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Riassunto 
L’immunoterapia basata sull’utilizzo di anticorpi non coniugati, coniugati a tossine o 
radiomarcati, che riconoscono antigeni associati a tumore, è promettente per la cura di 
tumori solidi o ematici. Un possibile target per l’immunoterapia potrebbe essere il 
prostate stem cell antigen (PSCA), un antigene appartenente alla famiglia delle “GPI-
anchored protein”. Il PSCA è un antigene di superficie espresso a bassi livelli nel 
tessuto prostatico sano ed over espresso nel tumore prostatico, pancreatico e della 
vescica. L’espressione di PSCA è inoltre correlata positivamente a “Gleason score” e 
allo stadio della patologia nel tumore prostatico. 
Il presente lavoro di tesi descrive la generazione e caratterizzazione di un anticorpo 
monoclonale murino anti PSCA (mAb), ottenuta tramite la tecnologia dell’ibridoma, e 
del suo frammento anticorpale a singola catena (scFv), generato clonando la regione 
variabile della catena leggera (VL) e della catena pesante (VH) nel vettore di espressione 
pHEN-2. Tramite citofluorimetria è stato dimostrato che l’anticorpo monoclonale 
possiede una buona affinità e specificità di legame all’antigene. Il potenziale 
diagnostico dell’anticorpo è stato dimostrato tramite Western Blot su lisati di tessuti 
neoplastici di prostrata e pancreas, in cui l’anticorpo è in grado di legare l’antigene 
denaturato e glicosilato, e tramite ELISA, in cui l’anticorpo si lega all’antigene espresso 
da cellule precedentemente fissate. Il potenziale terapeutico dell’anticorpo è stato 
valutato tramite saggio di proliferazione: l’anticorpo da solo non è in grado di indurre 
morte cellulare tramite un meccanismo diretto, mentre in seguito a coniugazione 
chimica con la catena A della ricina (RTA) rivela effetto citotossico su cellule PC-3 
hPSCA con IC50 (concentrazione in grado di inibire la massima proliferazione cellulare 
del 50%) pari a 1.3x10-9, valore 100 volte più piccolo di quello ottenuto con la sola 
tossina RTA. 
Il frammento scFv è stato prodotto nel ceppo batterico E. Coli. Mediante analisi 
citofluorimetrica su cellule PSCA positive e saggio immunoenzimatico sull’antigene 
ricombinante è stato verificato che il frammento anticorpale mantiene le stesse 
caratteristiche di specificità di legame all’antigene dell’anticorpo monoclonale 
parentale, ma possiede affinità minore. Quando l’ scFv viene reso bivalente, tramite il 
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cross-linking dei monomeri utilizzando un anticorpo anti-myc, l’affinità raggiunge 
quasi quella dell’anticorpo parentale. 
Successivamente l’scFv è stato unito attraverso fusione genetica al dominio enzimatico 
della tossina batterica Pseudomonas aeruginosa exotoxin A (PE40). L’immunotossina 
risultante è espressa nel ceppo batterico E. Coli e si accumula nei corpi d’inclusione. 
L’analisi citofluorimetrica su cellule PSCA positive fatta utilizzando i corpi 
d’inclusione rinaturati e contenenti l’immunotossina di fusione ha confermato che 
l’interazione tra l’scFv e l’antigene viene conservata in seguito alla fusione con la 
tossina PE40. 
L’effetto citotossico dell’immunotossina purificata scFv-PE40 verrà valutata prima in 
vitro su linee cellulari PSCA positive e negative e poi in modelli in vivo che 
permetteranno di valutare anche eventuali effetti collaterali. 
 
Abstract 
Antibody-based therapy using unconjugated, toxin-conjugated or radiolabeled 
immunoglobulins recognizing tumor-associated antigens has proven beneficial for solid 
and hematolymphoid neoplasms. A suitable target could be prostate stem cell antigen 
(PSCA), a member of the “GPI-anchored protein”. PSCA is a cell surface-antigen 
expressed at low levels in normal prostate tissue and over expressed in prostate, 
pancreatic and bladder carcinomas. Moreover PSCA expression is positively correlated 
with Gleason score and with pathologic stage in prostate cancer. 
The present thesis describes the generation and characterization of the murine anti 
PSCA monoclonal antibody (mAb), obtained by hybridoma technology, and its 
fragment single chain (scFv), generated by cloning the variable heavy (VH) and light 
(VL) chain sequences in the expression vector pHEN-2. The mAb showed the ability to 
recognize with good affinity and specificity the native PSCA by flow cytometry. The 
diagnostic potential of the mAb was demonstrated by Western Blot performed with 
prostate and pancreatic neoplastic tissue lysates, showing the binding to denaturated and 
glycosylated PSCA, and by ELISA performed with fixed cells. The mAb was also 
assessed for its possible use in the therapeutic approach: the cell-proliferation assay 
demonstrated that the antibody alone is not able to induce cell death through a direct 
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mechanism, while when it is conjugated to the ricin A chain toxin (RTA) by chemical 
linkage it can poison PC-3 hPSCA cells with an IC50 (i.e. concentration inhibiting 50% 
of the maximal cell proliferation) of 1.3x10-9 M, value 100 fold lower than the IC50 of 
the RTA toxin alone. 
The scFv was produced in E. Coli bacteria; flow cytometric analysis on PSCA-positive 
cells and immunoenzymatic assay on the recombinant antigen proved that the antibody 
fragment maintains the binding specificity of the parental monoclonal antibody. The 
affinity of the scFv is lower than the affinity of mAb but it is partially recovered making 
the scFv divalent by cross-linking the scFv monomers via an antibody-mediated myc- 
Tag interaction. 
To create a fusion immunotoxin (IT) the scFv was later genetically fused to the 
enzymatic domain of Pseudomonas aeruginosa exotoxin A (PE40). The resulting IT 
was expressed in E. Coli bacteria and it is accumulated in the inclusion bodies. The flow 
cytometric analysis on PSCA-positive cells performed with the whole refolded 
inclusion bodies extract containing the fusion IT confirmed that the interaction of scFv 
with the PSCA is preserved after fusion to PE40. 
The efficacy of purified scFv-PE40 will be analyse in vitro on positive and negative cell 
lines and subsequently in vivo models which also will be useful to study the side effects 
of this new drug. 
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Conventional cancer therapies 
The first description of a disease resembling cancer is found in an Egyptian papyri and 
dates back to approximately 1600 bc. Nevertheless, until the nineteenth century, when 
anaesthesia, improved techniques and histological control made surgery more efficient, 
cancer was more or less regarded as incurable. Radiation therapy became the next 
treatment available for cancer. In fact, the invention of the linear accelerator in the first 
half of the twentieth century advanced radiotherapy from a palliative method to a cancer 
treatment with a curative intent. However, both surgery and radiation were in most 
cases not sufficient to control metastastic cancer. Moreover, the increase in the 
incidence of cancer stressed the need to find other forms of therapy for this disease. 
The introduction of nitrogen mustards in the 1940s can be considered the origin of 
antineoplastic chemotherapy targeting all tumour cells [Papac, 2001]. Agents that 
inhibit cancer growth (chemotherapy) were generally cell toxic with severe side effects. 
Further classes of cell toxic agents were discovered during the 1950-70s. Gradually, 
chemotherapy has been introduced in various tumor forms, as palliative treatment to 
relieve symptoms and increase the quality of life in late stages of the disease, or in 
conjunction with surgery and/or radiotherapy, in order to increase cure rates.  
In general, there has been a trend towards using combinations of chemotherapy agents 
with different mechanisms of action to achieve maximal effect.  
Nevertheless, these strategies usually lack specificity of action towards tumor cells, 
which accounts for the variety of possible side effects inherent in these types of 
therapies. 
Radiotherapy, consisting in directing ionizing radiations on the tumor mass to damage 
the cancerous cells and in particular their nucleic acids, can lead to DNA mutations in 
the by-stander normal cells [Suit et al., 2007]. The selectivity of the cytotoxic agents 
used in chemotherapy, for instance, is based on the higher liability of rapidly 
proliferating cells to the toxic effect of these drugs; the major drawback of this approach 
is the toxicity towards healthy tissues with a rapid cell turnover [Schrama et al., 2006].  
Some indolent malignancies, due to their slow progress, respond poorly to conventional 
treatments. Besides, tumor cells can develop a resistance to chemotherapy drugs, 
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hindering their mechanism of action or promoting their expulsion out of the cell before 
they can act [Perez-Tomas, 2006; O’Connor, 2007]. 
As a consequence, the need for an improved efficacy in cancer therapies has been 
increasingly felt in the last few years, placing the focus of research on the development 
of new drugs that combine power of action and selective targeting of cancerous cells. 
An ever clearer understanding of the biochemical events that are implicated in the onset 
and progression of many malignancies has allowed the designing of tumor-specific 
therapies that directly target the molecules involved in the development of tumors or 
that selectively deliver the drug to cancerous cells. The opportunity of specifically 
affecting a tumor is provided by the presence of molecular targets being selectively 
expressed on the surface of cancerous cells: these are the tumor marker antigens 
[Schrama et al., 2006]. 
Rising of immunotherapy 
The body has many defence mechanisms against intrusion/infection. One cornerstone in 
this defence system is antibodies, large molecules with the ability to bind to proteins 
(antigens). As early as the beginning of the 20th century, scientists suggested the 
potential for using the body’s own defence systems treating cancer. In the 1968, Porter 
and Edelman managed to identify and structurally characterize a class of serum proteins 
that could bind a virtually unlimited variety of molecular targets with high specificity: 
the immunoglobulins. Few years later, in 1975, immunoglobulins became available as 
tools for research and clinical purposes thanks to the development of the hybridoma 
technology by Köhler e Milstein,  which allowed the custom generation and large-scale 
production of monoclonal antibodies (mAbs) of murine origin [Köhler and Milstein, 
1975; Schrama et al., 2006]. 
Since the early 80’s more than 200 mAbs with anti-cancer potential have been evaluated 
in clinical trials by academic and private institutions. Although the first attempts failed 
to provide a clear evidence of beneficial effects on patients, antibody-based drugs 
(immunotherapeutics) have by now become important elements in the treatment of an 
increasing number of human malignancies. To date twelve mAbs for cancer treatment 
have been approved and marketed, with the first one, an antibody for the therapy of 
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colorectal cancer, approved in Germany in 1995 (eventually withdrawn from the 
market) [Reichert et al., 2005; Reichert and Valge-Archer, 2007]. 
Antibody-based targeted therapy 
The antibody-based targeted therapy of cancer comprises different strategies that can be 
divided in two main categories: direct and indirect. 
Direct strategy 
The direct approach implies the binding of unconjugated antibody to a specific cell-surface 
antigen. This can lead to: an altered signal transduction pathway, the triggering of a natural 
immune response (ADCC: Antibody Dependent Cellular Cytotoxicity, CDC: Complement 
Dependent Cytotoxicity) or the induction of apoptosis in the malignant cell (Fig. 1) [Adams 
and Weiner, 2005; Sharkey and Goldenberg, 2006]. 
• Antibody dependent cellular cytotoxicity (ADCC) 
It occurs when antibodies bind to antigens on a tumor cell and their Fc portions 
engage Fc receptors (FcR) on the surface of immune effector cells. This kind of 
mechanism favours recruitment of immune cells to the tumor site and allows 
eliciting of an immune-mediated tumor-specific cytotoxicity. 
• Complement dependent cytotoxicity (CDC) 
Binding of an antibody on the target cell surface exposes its binding sites for 
protein that initiate the complement cascade, ultimately triggering the release of 
chemotactic factors and the formation of a membrane attack complex which 
promote target cell lysis. 
• Signal transduction interference 
Some of the most common tumor-specific targets are growth factor receptors 
which are frequently overexpressed or deregulated on tumor cells. Their 
overexpression or abnormal activity promotes tumor cell growth and 
insensitivity to chemoterapeutic agents. For this reason they are good targets for 
immunotherpeutic approaches. 
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Unconjugated antibodies (i.e. immunoglobulins not coupled to any effector molecule) 
can be used in a direct approach, but they are not always able to induce the killing of 
target cells.This is because malignant cells can be very resistant to the induction of 
apoptosis and the immune system of the patient can be defective in triggering responses 
like ADCC or CDC. 
Indirect strategy 
The indirect strategy enhances the efficacy of antitumor antibodies by arming them by 
covalent linkage to effector molecules (Fig. 2) [Schrama et al., 2006]. 
Figure 1. Mechanisms of action for unconjugated antibodies. Traditional mechanisms of action 
include antibody-dependent cell cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). 
Both require the Fc-portion of the IgG to activate effector cell binding or complement proteins that can 
lead to the death of the cells. However, antibodies that bind to growth factor receptors on the surface of 
the tumor cell (such as EGFR) can block critical functions and send signals that will lead to the cell's 
death. Alternatively, antibodies can bind to substances produced by tumors, such as VEGF, that are 
essential for stimulating new blood vessel formation, thereby inhibiting new tumor growth. (Modified 
from Sharkey and Goldenberg, 2008). 
Introduction 
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Figure 2. Strategies for enhancing the potency of antitumour antibodies. (a) Enhancing effector 
functions involve improving antibody-dependent cellular cytotoxicity and/or complement-dependent 
cytotoxicity by means of site-directed mutations or manipulation of antibody glycosylation. (b) Direct 
arming of antibodies entails their covalent linkage to killing machinery, such as radionuclides or toxins 
(for example, small molecules or proteins). Alternatively, arming antibodies with cytokines is intended to 
create high intratumour concentrations of cytokines to stimulate the antitumour immune response (T cells, 
B cells or natural killer cells), while avoiding the toxicities associated with systemic cytokine delivery. (c) 
Indirect arming of antibodies can be achieved by attaching engineered antibody fragments to the surface 
of liposomes loaded with drugs or toxins for tumour-specific delivery. Bispecific antibodies that bind to 
two different antigens can be preloaded with the cytotoxic machinery before administration (indirect 
arming) or alternatively pre-targeted to the tumour before delivery of the cytotoxic payload. (d) Pre-
targeting strategies aim for the selective delivery of radionuclides to tumours or selective intratumour 
activation of prodrugs, thereby diminishing the systemic toxicities of these cytotoxic agents. For prodrug 
pretargeting, an antibody-fragment–enzyme fusion protein is typically allowed to localize to a tumour and 
be cleared from the system. A prodrug is then administered and ideally converted to an active drug solely 
within the tumour. For radionuclide pre-targeting, an antibody–streptavidin conjugate is allowed to accrue 
within a tumour and is then used to capture a biotin–chelator–radionuclide complex. scFv, single-chain 
variable fragment (Modified from Carter, 2001). 
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The cytotoxic power of antibodies can be greatly augmented by chemical conjugation or 
genetic fusion with effector molecules like toxins, drugs, cytokines or enzymes [Pastan 
et al., 2006]. Another option is the conjugation to compounds containing radionuclides 
like 90Y and 131I [Wu and Senter, 2005]. These immunotherapeutic agents derive their 
killing ability from the toxic moiety and their selective binding from the antibody to 
which the toxic agent is coupled [Pastan et al., 2006]. In addition to the function of 
targeted delivery, the antibody often grants an enhanced half-life on the toxic moiety 
attached to it [DiJoseph et al., 2005]. 
 
Among the twelve monoclonal antibodies currently marketed for use in immunotherapy 
(Table 1), eight are naked antibodies, three are labelled with radionuclides and one is 
chemically conjugated to a toxic moiety, calicheamicin [Reichert and Valge-Archer, 
2007; Reichert et al., 2005]. 
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Generic name (trade 
name)
Description First approval indication 
Year (country) of 
first approval
Unconjugated mAbs
Edrecolomab 
(Panorex)
Murine, IgG2a, anti-EpCAM Colorectal cancer 1995 (Germany)*
Rituximab (Rituxan) Chimeric, IgG1, anti-CD20 Non-Hodgkin’s lymphoma 1997 (United States)
Trastuzumab 
(Herceptin)
Humanized, IgG1, anti-HER2 Breast cancer 1998 (United States)
Alemtuzumab
(Campath)
Humanized, IgG1, anti-CD52
Chronic lymphocytic 
leukemia
2001
Cetuximab (Erbitux) Chimeric, IgG1, anti-EGF 
receptor Colorectal cancer 2004
Bevacizumab
(Avastin)
Humanized, IgG1, anti-VEGF
Colorectal cancer
Non small-cell lung cancer
Advanced Breast cancer
2004
2006
2008 (United States)
Nimotuzumab 
(TheraCIM)
Humanized, IgG1,
anti-EGF receptor
head/neck
epithelial cancer
2005 (China)
Panitumumab 
(Vectibix)
Human, IgG2,
anti-EGF receptor
Colorectal cancer 2006 (United States)
Immunoconjugates 
Gemtuzumab
ozogamicin
(Mylotarg)
Humanized, IgG4 k, anti-
CD33, immunotoxin
(calicheamicin)
Acute myelogenous
leukemia (AML)
2000 (United States)
Ibritumomab tiuxetan 
(Zevalin)
Murine, IgG1, anti-CD20, 
radiolabelled (Y-90)
Non-Hodgkin’s 
lymphoma
2002 (United States)
131ITositumomab 
(Bexxar)
Murine, IgG2a, anti-CD20, 
radiolabelled (I-131)
Non-Hodgkin’s lymphoma 2003 (United States)
131I ch-TNT
Chimeric, IgG1k, anti-DNA 
associated antigens,
radiolabelled (I-131)
Lung cancer 2003 (China)
 
Table 1. Monoclonal antibodies approved for cancer therapy (updated from Reichert and Valge-
Archer, 2007; Sharkey et al., 2008). *Panorex was subsequently withdrawn from market. EGF, epidermal 
growth factor; EGFR, epidermal growth factor receptor; EpCAM, epithelial cell adhesion molecule; 
HER2, human epidermal growth factor receptor 2; VEGF, vascular endothelial growth factor. 
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Tumor antigens 
One of the distinguishing events occurring during the neoplastic transformation of a cell 
is the abnormal expression of some surface molecules like proteins or glycoproteins 
acting as receptors or adhesive elements. These “tumor markers” are classified as:  
• Tumor Specific Antigens (TSAs), that are relatively rare. They could arise 
from point mutations in oncogenes or tumor suppressor genes such as ras in 
pancreatic and colorectal cancer [Gjertsen and Gaudernack, 1998] or p53 in lung 
cancer [Yanuck et al., 1993]. Moreover these antigens could derive from virally 
induced tumors, which constitute almost 20% of all human cancer [Stewart and 
Kleihues, 2003]. 
• Tumor Associated Antigens (TAAs), more common. These antigens are shared 
by the tumor, where they are overexpressed, and the tissue from which the tumor 
originates, where they are expressed at lower level. This group comprises 
differentiation antigens and has mainly been found in melanomas and 
melanocytes, e.g. Melan-A [Coulie et al., 1994] and tyrosinase [Brichard et al., 
1993] but also in other epithelial tissues such as prostate specific antigen (PSA) 
found in prostate.  
• Oncofetal proteins (CEA, alphafetoprotein) are normally expressed transiently 
in embryonic tissues, down-regulated in normal adult tissues, and re-expressed 
in tumor tissues.  
 
These types of molecules, whether specific of cancerous cells or associated with the 
transition to neoplastic phenotype, represent the potential targets of cancer 
immunotherapy.  
On each malignant cell there are multiple distinct sites that may become target antigens 
for a therapeutic antibody, which allows to fight cancer on many fronts, thus 
diminishing the chances of “escape” by the tumor [Urban and Schreiber, 1992]. Within 
a population of neoplastic cells there might be individual cells in which a particular 
target antigen is lacking or its expression is repressed; many experimental evidences 
indicate that targeting different surface proteins remarkably improves the therapeutic 
efficacy of the treatment [Flavell et al., 1997]. 
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An ideal target antigen, displayed on the surface of a tumor cell, must be accessible, 
comparatively over-expressed on malignat cells, uniformly distributed; it should not be 
secreted or shed after binding to ligands and, depending on the mechanism of action of 
the drug, it should or should not be internalized. For instance, in the case of a 
therapeutic mAb whose activity is mediated by ADCC or CDC, the antigen-antibody 
complex must not be internalized into the cell, otherwise the Fc portion of the antibody 
will be unable to recruit other elements of the immune system. On the contrary, 
endocytosis is necessary for delivering the full cytotoxic potential of most 
immunotoxins (Fig. 3): the target in this case must undergo ligand-induced 
internalization or should alternatively possess an inherently high frequency of turn-over, 
thus promoting the efficient transfer of the toxic domain into the cell [Reichert and 
Valge-Archer, 2007]. 
 
 
Figure 3. Internalization of antibody–drug conjugates. To regain their cytotoxic activity, the cytotoxic 
agent has to be cleaved from the chemo-immunoconjugate. Uptake of antibodies predominantly occurs 
via the clathrin-mediated endocytosis pathway. After binding the respective antigen associated with 
coated pits, antibody–drug conjugates will be readily endocytosed, from where they transit through 
several stages of transport and endosomal vesicles and finally end up in a lysosome. There, linkers and 
antibody will be cleaved releasing the cytotoxic agent which — after exit from the lysosomal 
compartment — exerts its cytotoxic effect. (Modified from Schrama et al., 2006). 
Introduction 
12 
 
Monoclonal antibodies 
The antibodies used in cancer diagnosis and therapy are derived from the IgG isotype. 
An IgG isotype antibody consists of two antigen-binding fragments (Fabs), which are 
connected via a flexible region (the hinge) to a constant (Fc) region (Fig. 4). This 
structure comprises two pairs of polypeptide chains, each pair containing a heavy and a 
light chain of dissimilar sizes. Both heavy and light chains are folded into 
immunoglobulin domains. The ‘variable domains’ in the amino-terminal part of the 
molecule are the domains that identify and bind antigens; the rest of the molecule is 
composed of ‘constant domains’ that vary among immunoglobulin classes. The Fc 
portion of the immunoglobulin serves to bind a variety of effector molecules of the 
immune system, as well as molecules that establish the biodistribution of the antibody 
[Trail et al., 2003]. In nature, an antibody’s function is to recognize an antigen and, by 
cross reaction with other immune proteins, to initiate an immunological response. This 
response should direct the removal of the antigen or the cell bearing the antigen as a 
result of the antigen/antibody recognition. 
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Monoclonal antibodies (mAbs) were originally developed by Köhler and Milstein in 
1975 when they successfully fused an antibody-producing B cell with an immortalized 
myeloma cell line resulting in a hybridoma [Köhler and Milstein, 1976]. These 
hybridoma cells could then be cloned and screened for large-scale production of mAb 
[Brekke and Sandlie, 2003]. Many therapeutic antibodies currently under clinical 
evaluation were initially derived by immunization of mice and classic hybridoma 
technology. A major factor limiting repeated dosing of fully murine mAbs in humans 
was that the Fc region of the immunoglobulin structure was murine in origin [Mirik et 
al., 2004]. After intravenous administration of these mAbs, patients developed human–
antimouse antibodies (HAMAs) that were shown to complex with murine mAbs upon 
repeat administration and in some cases led to acute anaphylactic or chronic serum 
sickness-like illness [McLaughlin et al., 1998; Kim, 2003]. 
Molecular engineering techniques have overcome this obstacle by creating chimeras by 
fusing murine variable domains, responsible for the binding activity, with human 
Figure 4. Schematic diagram of immunoglobulin structure. Each heavy and light chain in an 
immunoglobulin molecule contains an amino-terminal variable (V) region that differs between antibodies 
of distinct clonality. The constant region (C) exhibit a limited variability that defines the two light-chain 
subtypes (k e λ) and the five heavy-chain subclasses (α, γ, δ, ε, µ). The molecule represented is 
specifically an IgG, with a heavy chain comprising three constant domains (one of them, CH2, 
glycosilated) and a proline-rich hinge region connecting CH2 and CH1. 
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constant domains [Neuberger et al., 1985] leading to the development of a new 
generation of therapeutic candidates [Reichert et al., 2005] (Fig. 5). These chimeric 
antibodies are 70% human and possess a fully human Fc portion, which makes them 
considerably less immunogenic in humans and allows them to interact with human 
effector cells and the complement cascade. With the development of antibody 
engineering techniques, it became possible to decrease even further the murine part of 
mAbs by replacing the hypervariable loops of a fully human antibody with the 
hypervariable loops of the murine antibody of interest, using an approach called 
complementarity-determining region grafting [Jones et al., 1986]. These antibodies, 
called ‘humanized’, are 85–90% human and are even less immunogenic than chimeric 
antibodies (Fig. 5). Most of the approved mAbs in current use are either chimeric or 
humanized (Table 1). 
 
 
Figure 5. Chimeric and humanized antibodies. Murine sequences are depicted in red and human 
sequences in green, using light colours for light chain and dark colours for heavy chains. (Modified from
Chames et al., 2009) 
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Monoclonal antibody fragments 
Many studies have demonstrated that it is possible to produce various antibody 
fragments that retain the binding activity of the full-length molecule (Fig. 6) and to use 
these new formats in certain specific applications [Holliger and Hudson, 2005]. The 
large size of antibodies limits tumor penetration, and their long serum half-life is not 
suitable for applications such as radioimmunotherapy or imaging as it would lead to 
irradiation of healthy tissues and high background respectively. Antibody fragments, 
such as F(ab)2 and Fab fragments generated only by proteolytic cleavage, although they 
lack an effector function, can be an attractive alternative as they are rapidly eliminated 
by renal clearance. To compensate for these shortcomings, several groups have 
proposed new engineered antibody formats. 
A major breakthrough in the technology of antibody engineering was the derivation of 
single-chain molecules (scFv fragments). These molecules were obtained by joining the 
variable heavy (VH) and light (VL) domains from an antibody with a flexible linker, 
which allowed the reconstitution of the original VH/VL association (Fig. 6). In this way, 
an antibody fragment was produced in the form of a single-chain molecule, and its 
antigenic specificity was retained [Bird et al., 1988]. Because of their reduced size (28 
kDa), recombinant scFv fragments demonstrated a high tumor penetration and a very 
rapid plasma clearance, features that make them ideal tools for radioimmunodiagnostic 
purposes [Yokota et al., 1992]. These antibody molecules potentially can be used not 
only for tumor diagnosis (imaging) but also for the development of chimeric proteins in 
which the recombinant antigen-binding domain is fused to a cytotoxic agent, such as a 
cytotoxic drug, radioisotope [Begent et al., 1996; Adams et al., 1998], or a protein toxin 
[Reiter and Pastan, 1998; Kreitman, 1999]. 
It has been shown that alteration of the V-domain orientation of scFv as well as linker 
length between V-domains leads to creation of new forms of Fv modules with different 
size, flexibility and valency suited for in vivo imaging and therapy. This led to the 
design and expression of dimers, trimers or larger aggregates of antibody fragments 
[Todorovska et al., 2001; Le Gall et al., 1999]. A number of multivalent scFv-based 
structures have been engineered, including dimeric (minibodies or diabodies), trimeric 
(trivalent or trispecific) or tetrameric (tetravalent or tetraspecific) conjugates [Hudson, 
1999; Hudson and Kortt, 1999; Bauer et al., 1999] (Fig. 6). Generally, in comparison to 
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the intact antibodies, the recombinant antibodies demonstrate lower retention time in 
non-target tissues, rapid blood clearance, lower quantitative tumor retention and a better 
tumor penetration due to their small size [Yokota et al., 1992; Raag and Whitlow, 1995; 
Milenic et al., 1991]. 
Bispecific antibodies have the ability to bind two different antigens and have been used 
to crosslink various cells and molecules, although they have primarily been used to 
redirect effector cells to target cells. For example, single-chain Fv fragments derived 
from monoclonal antibodies against a variety of tumor-associated antigens, such as 
CD19, CD20, and HER2/neu, were combined with scFv directed against CD3 or CD16 
to recruit effector T-cells or NK cells [Peipp et al., 2002; Xiong et al., 2002]. Methods 
for generating bispecific antibodies tend to bias the production toward heterodimers, 
that is, towards two specificities instead of one. 
 
IgG
150 kDa
Enzymatically derived fragments
F(ab)2 Fab
scFv
Genetically engineered fragments
110 kDa 55 kDa
28 kDa
Diabody Minibody Triabody
55 kDa 75 kDa 75 kDa
Tetrabody
100 kDa
 
 
 
Figure 6. Schematic representation of different antibody format. The domain-based structure of 
immunoglobulins could be manipulated to yield a wide repertoire of antibody formats from 28 kDa to 100 
kDa in size. The orange colour symbolizes different specificity. (Modified from Holliger and Hudson, 
2005). 
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Immunotoxins 
Immunotoxins (ITs) employed in cancer therapy comprise a toxic, usually 
proteinaceous, portion linked to a binding domain that delivers the complex to the target 
cell [Kreitman, 2006]. ITs interact with a surface target antigen, gain access into the 
malignant cell by endocytosis, the toxic subunit is released and kills the cell; the most 
powerful ITs that have been developed so far are based on bacterial or plant toxins 
[Pastan et al., 2007]. 
First-generation ITs were obtained by chemically conjugating one whole toxin to a mAb 
(Fig. 7a); these ITs often showed no tumoral efficacy in animal models because they 
lacked specificity, were unstable or not homogeneous in composition. Information 
gathered from structural studies on toxins have defined the functional domains of these 
proteins, thereby allowing a more rational design of novel ITs. Replacement of the toxin 
natural binding domain with an antibody-derived domain led to the development of 
second-generation ITs (Fig. 7b) . As for first-generation ITs, the binding domain and the 
toxic portion are chemically linked, with the persistent problem of heterogeneous 
composition of the final immunoconjugate [Pastan et al., 2007; Pastan, 2003]. 
Third-generation immunotoxins are based on the principles of protein engineering and 
exploit recombinant DNA technology: the domain with toxic activity alone is genetically 
fused to a defined binding domain that targets a tumor surface antigen [Kreitman, 2006; 
Pastan et al., 2007] (Fig. 7c).  
For therapeutic efficacy, the conjugates have to be internalized into the cell upon binding to 
their respective ligands. The cell-killing potency of immunotoxins depends on several 
biochemical properties, such as antigen-binding affinity, internalization rate, intracellular 
processing and intrinsic toxin-domain potency [Hexham et al., 2001]. 
In the last 10-15 years several recombinant immunotoxins have been evaluated in clinical 
trials (Table 2). 
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Figure 7. Schematic diagram of immunotoxins. (a) First-generation immunotoxins: the whole toxin (T, 
toxic domain, and B, binding domain) is chemically conjugated to mAb by disulphide bond. (b) Second-
generation immunotoxins: only the toxic domain is chemically conjugated to mAb by a disulphide bond. 
(c) Third-generation immunotoxins: only the toxic domain is genetically fused to the antibody domain.
(Modified from Chames et al., 2009). 
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Agent Target antigen Binding domain Toxic domain Diseases
DAB389IL2 (Ontak) IL2R IL2 DAB389 CTCL, CLL, NHL
BL22 CD22 dsFv PE38 HCL, CLL, NHL
LMB2 CD25 scFv PE38 NHL, Leukemias
DT388-GMCSF GMCSFR GMCSF DT388 AML
B3(Fv)-PE38 Ley scFv PE38 Adenocarcinomas
B3(dsFv)-PE38 Ley dsFv PE38 Adenocarcinomas
TP40 EGFR TGFa PE40 Bladder Cancer, CIS
TP38 EGFR TGFa PE38 Glioblastoma
BR96(scFv)-PE40 Ley scFv PE40 Adenocarcinomas
erb38 erbB2 dsFv PE38 Breast cancer
NBI-3001 IL4R IL4(38-37) PE38KDEL Glioma
IL13-PE38QQR IL13R IL13 PE38QQR Glioblastomas
SS1(dsFv)-PE38 Mesothelin dsFv PE38
Mesothelioma, ovarian 
and pancreatic cancers
DAB389EGF EGFR EGF DAB389 Carcinoma
TP-38 EGFR TGFa PE38 Glioblastomas
 
Table 2. Completed and ongoing recombinant immunotoxin clinical trials as of 2006 (modified from 
Kreitman, 2006 and Pastan et al, 2006). Abbreviations: IL2, interleukin 2; IL2R, IL2 receptor; GMCSF, 
granulocyte-macrophage colony-stimulating factor; GMCSFR, GMCSF receptor; Ley, Lewis Y antigen; EGF, 
epidermal growth factor; EGFR, EGF receptor; TGFα, transforming growth factor α; IL4, interleukin 4; IL4R, 
IL4 receptor; IL13, interleukin 13; IL13R, IL13 receptor; IL4(38-37), circularly permuted IL4;  DT, diphteria 
toxin; DAB389 and DT388, truncated DT; PE, Pseudomonas exotoxin  A; PE38, PE40, PE38KDEL and 
PE38QQR are all truncated versions of PE.  
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Binding domain 
In the design of an IT a variety of  binding domains can be used to selectively deliver 
the drug to the intended cell target; besides monoclonal antibodies and fragments thence 
derived, other small proteins are appropriate to fulfil this function, e.g. growth factors 
and cytokines. Such molecules impart specificity to the IT by virtue of the higher 
expression level of some receptors for growth factors and cytokines on tumor cells. 
Interleukin 2 (IL-2) and the Granulocyte-Macrophage Colony Stimulating Factor 
(GMCSF), for instance, have been employed in the construction of immunotherapeutic 
agents to direct toxic molecules towards leukemia or lymphoma cells [Frankel et al., 
2002; Olsen et al., 2001]. 
However, due to their remarkable molecular versatility and to the possibility of being 
raised against virtually any target, antibodies are probably the best candidates as binding 
domains in ITs design [Kreitman, 2006]. 
Toxic domain 
In the design of a therapeutic IT, protein toxins proved the best candidates as cytotoxic 
domains: due to their polypeptidic structure they are intrinsically flexible and usually 
show a high stability, resisting high temperatures and proteolysis. Moreover, in most 
cases the protein toxin is an enzyme with a fast turnover rate, and it is capable of killing 
both dividing and resting cells and therefore potentially able to kill tumors that are not 
actively growing at the time of treatment and that would scarcely respond to traditional 
chemotherapy [Vitetta et al., 1993]. The major disadvantage inherent in the employment 
of a protein toxin of non-human origin lies in its likely immunogenicity [Pastan et al., 
2006]. 
Small, pharmachologically active molecules like vinblastine and chalicheamicin have 
been also studied as putative toxic moieties in ITs. However, they are often unable to 
reach the target cells at concentrations sufficient to produce a therapeutic effect and, 
contrary to protein toxins, they have no enzymatic activity. Another drawback is that 
they can be attached to the binding domain of an IT only through chemical conjugation 
[Reichert and Valge-Archer, 2007]. 
The toxins that best fit the role of effector domain in an immunotoxin are the ones 
whose catalytic activity interferes with such conserved mechanisms as protein synthesis 
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that take place in most cell types. Some of the most potent ITs are based on toxins of 
bacterial or plant origin. Once these ITs reach their target site, a single molecule is 
capable of killing the targeted cell [Pastan et al., 2007; Kreitman, 2006]. 
Plant toxins 
Toxins of plant origin have been studied as potential drugs for cancer therapy; RIPs 
(Ribosome-Inactivating Proteins) are toxins that can be found stored in the seeds of 
some plant species and they represent the class of plant toxins most widely used for the 
purpose of immunotoxin construction. 
RIPs (e.g. ricin, abrin) are heterodimeric proteins of molecular mass of approximately 
60-65 kDa, consisting of an enzimatically active A-chain (A = active) connected by a 
disulfide bond to a B-chain (B = binding) (Fig. 8). The A-chain prevents the association 
of elongation factors 1 and 2 (eEF1 and eEF2) with the 60S ribosome subunit, by means 
of the specific removal of an adenine from the sugar-phosphate scaffold in 28S rRNA. 
This puts a halt to protein synthesis and the cell rapidly dies [Kreitman, 2006; Fabbrini 
et al., 2003]. The B-chain has the properties of a lectine specific for terminal galactose 
and N-acetylgalactosamine and binds to galactosyl-terminated receptors on the cell 
surface, thus allowing the toxin internalization. Following endocytosis, the whole toxin 
is sorted to endosomes, lysosomes and finally the Golgi complex; thence ricin passes to 
the endoplasmic reticulum by a retrograde routing, where the disulphide bridge that 
holds together the two chains (A and B) forming the toxin is reduced, thus allowing the 
release of the catalytically active A chain, which is eventually retrotranslocated to the 
cytosol and exerts its toxic effect on ribosomes [Fabbrini et al., 2003; Bagga et al., 
2003]. 
Because the enzymatic domain alone is involved in the intoxication of the cell, plant 
RIPs are reduced and the A-chain (e.g. RTA) is exploited for the creation of ITs (Fig. 8) 
[Kreitman, 2006].  
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Bacterial toxins 
Pseudomonas aeruginosa Exotoxin A (PE) and Corynebacterium diphtheriae toxin 
(DT) are the bacterial toxins more widely exploited for immunotherapy. They are both 
protein toxins that kill eukaryotic cells by catalysing the transfer of the ADP-ribose 
group from a NAD+ molecule to a modified residue of histidine, also called 
diphthamide, which is present in the eukaryotic elongation factor 2 (eEF2), which 
determines the inhibition of protein synthesis. In spite of their having a common 
mechanism of action and similar size (66 kDa for PE and 60 kDa for DT), the two 
proteins do not show a high degree of sequence homology [Pastan and FitzGerald, 
1989]. 
Differently from ricin, both PE and DT are macromolecules constituted by a single 
polypeptide chain organized in three functional portions: a binding domain mediating 
the interaction with the cell surface, a domain implicated in the translocation of the 
toxin into the cytosol and another one which is responsible for the ADP-ribosylating 
enzymatic activity (Fig. 9). In Pseudomonas exotoxin A, the catalytic domain is located 
at the C-terminus, whereas it is at the N-terminal end of DT [Kreitman, 2006]. 
Figure 8. Plant toxins.  Whole plant toxins contain activity (A) and (B) binding domains disulfide-
bonded together. Reduction of disulfide bond results in ricin A chain (RTA), which has reduced toxicity. 
(Modified from Kreitman, 2006)  
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After entering the cell, the two toxins follow distinct intracellular pathways. 
• DT 
Before being internalized, DT is proteolitically processed at a specific site 
within the translocation domain; the two deriving subunits are held together via 
a disulphide bridge. The toxin eventually joins the precursor of the heparin-
binding EGF-like growth factor and is endocytosed. The low pH inside the 
endosomes causes the unfolding of the toxin and the reduction of the disulphide 
linking the two subunits. At this stage the two domains form a hairpin structure 
that generates a channel spanning the endosome membrane, through which the 
enzymatic domain is translocated to the cytosol: here an ADP-ribose group from 
a NAD+ molecule is trapped in the active site of DT and finally transferred to 
eEF2 [Kreitman, 2006; Potala et al., 2008]. 
• PE 
As shown in Fig. 10, PE binds to CD91, also called alpha2-macroglobilin 
receptor/low density lipoprotein receptor-related protein, and then is 
endocytosed. In the acidic endosome environment PE dissociates from CD91, 
Figure 9. Schematic structure of bacterial toxins. (A) DT is 535 amino acids in length and is composed 
of the enzymatic A domain (amino acids 1-193) and the binding B domain (amino acids 482-535). The 
translocation (T) domain is located in between. (B) PE is a single-chain 613 amino acids protein 
composed of the binding domain (amino acids 1-252 form the subdomain Ia; amino acids 365-404 form 
the subdomain Ib), translocating domain (domain II, amino acids 253-364), and enzymatic domain 
(domain III, amino acids 400-613). (C) PE40 is the 40 kDa truncated version of PE; it laks only in the 
binding domain Ia. 
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undergoes a conformational change, and is cleaved by the protease furin 
between residues R-279 and G-280 [Ogata et al., 1992]. This results in an N-
terminal fragment of 28 kD and a C-terminal fragment of 37 kD, the latter being 
composed of a portion of domain II, domain Ib, and all of the enzymatic active 
domain III [Ogata et al., 1990; Wedekind et al., 2001]. Both fragments are still 
connected by the disulfide bond between C-265 and C-287, encompassing the 
furin cleavage site. It is speculated that under the mildly acidic conditions in the 
endosomes, there is an unfolding event, possibly aided by the binding of 
chaperone proteins. This leads to a surface exposure of the disulfide bond with 
subsequent reduction which is followed by a release of the C-terminal 37-kD 
fragment [McKee and FitzGerald, 1999]. The enzymatic active 37-kD fragment 
travels via late endosomes in a Rab9-dependent manner to the trans-Golgi 
network (TGN). There, it can bind in a pH-dependent manner to the KDEL 
receptor via its C-terminal KDEL-like sequence REDL (aa 609–612) and is 
transported to the endoplasmic reticulum (ER) [Kreitman and Pastan, 1995; 
Jackson et al., 1999]. The KDEL receptor cycles between the TGN and the ER 
via Golgi cisternae with the help of the tyrosine kinase Src [Miesenbock and 
Rothman, 1995; Bard et al., 2003] and is responsible for recycling proteins 
bearing the C-terminal amino acid code KDEL to the ER [Wilson et al., 1993]. 
Alternatively, the 37-kD fragment of PE, which has bound to DRM (detergent 
resistant microdamain) at the cell surface, can directly reach the TGN from early 
endosomes in a pathway independent of the small GTPase Rab9 and presumably 
reaches the endoplasmic reticulum (ER) in a lipid-dependent sorting pathway, 
controlled by Rab6 [White et al., 1999; Smith et al., 2006]. Sequences in the 
translocation domain II induce the dislocation of the 37-kD fragment from the 
ER to the cytosol [Ogata et al., 1990; Theuer et al., 1993]. Once the enzymatic 
subunit of PE has reached the cytosol, it catalyzes the ADP ribosylation of its 
target protein, the eukaryotic elongation factor-2 (eEF-2) [Iglewski et al., 1977]. 
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PE is a preferred molecule for the construction of immunotoxins, because its high toxic 
potential is well documented and its cytotoxic pathways are well understood. For 
immunotoxin design, the receptor binding domain Ia (aa 1–252) of PE is removed and 
replaced by a ligand, which specifically binds to a tumor-associated antigen. The 
truncated form of PE (aa 253–613) is then known as PE40 to reflect its molecular 
weight of 40 kDa [Wolf and Elsässer-Beile, 2009]. 
A novel tumor associated antigen: prostate stem cell antigen 
(PSCA) 
The PSCA gene was originally identified through an analysis of genes up-regulated in 
the human prostate cancer LAPC-4 xenograft model [Reiter et al., 1998]. The PSCA 
gene is located on chromosome 8q24.2 and encodes a 123 amino acid cell surface 
protein with 30% homology to stem cell antigen type 2 (SCA-2), an immature 
Figure 10. Proposed mechanism of cell intoxication by Pseudomonas aeruginosa exotoxin A. The 
toxin binds the receptor and is eventually internalized through clathrin-coated vesicles. Inside endosomes, 
the protein is cleaved into two fragments, the C-terminal one being likely transported to the ER, whence 
the enzymatic domain of the toxin is expelled into the cytosol and ADP-ribosylates eEF2. (Modified from 
Pastan, I. et al., 2006). 
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lymphocyte cell surface marker. It is because of this relatively weak homology that 
PSCA was named inaccurately since it is not a marker for a stem cell population nor is 
it exclusively expressed in the prostate. PSCA bears multiple N-glycosylation sites and, 
like SCA-2, it  is a member of the Thy-1/Ly-6 family of glycosylphosphatidylinositol 
(GPI) anchored surface proteins. Additionally, a murine PSCA (mPSCA) homologue 
has been identified with 70% homology to human PSCA at the nucleotide and amino 
acid levels, which is located on chromosome 15 [Reiter et al., 1998]. 
The function of PSCA in normal cellular processes or carcinogenesis is currently 
unknown, however PSCA homologues shed light on a variety of possible roles. It has 
been previously shown that GPI-anchored proteins, like PSCA, play a role in T cell 
activation [Presky et al., 1990]. Additionally, proteins in the Thy-1 family have been 
reported to function in T cell activation and proliferation, stem cell survival, and 
cytokine and growth factor responses [Rege and Hagood, 2006]. Furthermore, the 
family of Ly-6 genes has been associated with carcinogenesis [Witz, 2000; Treister et 
al., 1998], cellular activation [Malek et al., 1986] and cell adhesion of tumor cells 
[Eshel et al., 2000]. While these studies point to potential roles of PSCA, no definitive 
function has been attributed to the protein either in normal cellular processes or 
abnormal tumorigenesis. 
PSCA expression in normal tissues 
With any potential immunotherapeutic target it is necessary to assess the normal tissue 
expression. Ideal targets show overexpression on target cells with limited or no 
expression on normal tissues, thereby reducing the risk of damage to normal tissues. 
PSCA messenger RNA (mRNA) expression in normal human tissues was found to be 
predominantly expressed in prostate, with a lower expression in placenta and a very low 
(1% of the level in prostate) amount in kidney and small intestine [Reiter et al., 1998, 
Cunha et al., 2006]. In situ hybridizations of normal human prostate sections found 
PSCA mRNA expression limited to the subjacent basal cells, with little or no staining of 
secretory luminal cells [Reiter et al., 1998]. In contrast, a separate study demonstrated 
that PSCA expression was localized to the secretory epithelial cells, with no expression 
in the basal cells or prostatic stroma [Ross et al., 2002]. This apparent disagreement in 
PSCA mRNA localization may be due in part to the relatively short half-life of mRNA 
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in tissues combined with the sampling error inherent in small sectional biopsies within a 
larger tissue. To clarify this discrepancy, another study analyzed PSCA protein in the 
prostate, a much more stable form of expression, using monoclonal antibodies (mAbs) 
and found PSCA protein to be present in both the basal and secretory epithelial cell 
layers, along with the neuroendocrine cells of the prostate [Gu et al., 2000]. 
Additionally, in this study PSCA protein expression was demonstrated in the placenta, 
the bladder, the neuroendocrine cells of the stomach and colon, and weakly in the 
kidneys excluding the glomeruli. 
PSCA expression in cancer 
In the initial study on PSCA expression in human prostate cancer, 102 of 126 (81%) 
primary human prostate tumors specimens along with seven of nine (78%) residual 
tumors removed after androgen ablation therapy stained strongly for PSCA using 
mRNA in situ hybridization [Reiter et al., 1998]. Analysis by immunohistochemistry 
(IHC) using an anti-PSCA mAb demonstrated 105 of 112 (94%) prostate tumors 
positive for PSCA, of which 21% stained very strongly and 63% stained moderately 
[Gu et al., 2000]. Importantly, this study also revealed a significant correlation between 
PSCA expression and Gleason score, pathologic tumor stage and progression to 
androgen-independence. A later study also significantly correlated high PSCA intensity 
with seminal vesicle invasion and capsular involvement [Han et al., 2004]. An 
additional study showed a higher percentage of metastatic prostate cancer cases staining 
positive for PSCA mRNA compared with nonmalignant prostate disease and organ-
confined prostate cancer [Ross et al., 2002]. Specifically, prostate cancer metastases to 
bone marrow, lymph node and liver stained positively for PSCA expression, with bone 
marrow metastases staining with comparatively higher intensity [Gu et al., 2000; Lam 
et al., 2005]. 
Whether overexpression of PSCA in humans is causative of prostate carcinogenesis 
remains unknown. Studies have shown chromosome 8q to be commonly amplified in 
metastatic and recurrent prostate carcinoma and associated with a poor prognosis 
[Visakorpi  et al., 1995, Sato et al., 1999]. Additionally, PSCA is located close to the c-
myc oncogene, and therefore PSCA expression may be increased incidentally with 
amplification of other genes shown to be up-regulated in prostate cancer [Jenkins et al., 
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1997, Qian et al., 1995]. These results also suggest that PSCA is a useful marker of 
MYC amplification on prostate cancer cells, allowing better characterization of each 
tumor [Jalkut and Reiter, 2002]. 
Of interest, subsequent to the identification of PSCA as a prostate tumor associated 
protein, several other tumors were evaluated for PSCA expression including pancreatic 
adenocarcinoma [Argani et al., 2001; Iacobuzio-Donahue et al., 2002; Wente et al., 
2005], transitional cell carcinoma [Elsamman et al., 2006; Amara et al., 2001], renal 
cell carcinoma [Elsamman et al., 2006] and diffuse-type gastric cancer [The Study 
Group of Millennium Genome Project for Cancer, 2008]. For pancreatic 
adenocarcinoma, overexpression of PSCA protein was established via IHC in 36 of 60 
(60%) primary tumors analyzed, while adjacent normal pancreas had no expression in 
59 of 60 samples [Argani et al., 2001]. Additional analysis of pancreatic cancer cell 
lines confirmed the cell surface expression of PSCA, making it a suitable target for 
immunotherapy [Wente et al., 2005]. When human transitional cell carcinoma (TCC) 
was studied, PSCA was expressed in a majority of TCC and a higher level of PSCA 
expression correlated with increasing tumor grade [Amara et al., 2001] and was an 
independent predictor of disease recurrence [Elsamman et al., 2006]. In addition, PSCA 
mRNA expression was increased in renal cell carcinoma and the gene expression level 
correlated with histological grade, pathological stage and prognosis [Elsamman et al., 
2006]. Finally, in an interesting recent article, polymorphism of the PSCA gene was 
shown to influence susceptibility to diffuse-type gastric cancer [The Study Group of 
Millennium Genome Project for Cancer, 2008]. 
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The PhD thesis here presented is focused on the generation of anti PSCA (prostate stem 
cell antigen) monoclonal antibody and its fragments as potential tools for diagnosis and 
therapy of carcinomas expressing the tumor associated antigen PSCA. 
 
The objectives of this project are: 
• generation of anti PSCA monoclonal antibody (mAb) and its fragment single 
chain (scFv); 
• characterization of their binding properties on both the purified recombinant 
PSCA and cells that express it on their cell surface; 
• evaluation of the diagnostic potential of mAb; 
• generation of chemical and genetically fused immunotoxins (IT); 
• evaluation of the selective toxicity of these IT on target cells; 
• generation of a cellular model of polarized epithelial tissue to study the efficacy 
of IT in polarized cells. 
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Escherichia Coli strains and growth media 
• BL21 (λDE3) and BL21 (λDE3) pLysS: growth in LB medium. 
BL21 (λDE3) pLysS are grown in medium containing 34 µg/ml chloramphenicol to 
maintain the selection of pLysS plasmid; 
• HB2151: growth in 2X YT medium. 
 
LB-medium 
Tryptone 10 g/l 
Yeast Extract 5 g/l 
NaCl 10 g/l 
 
2X YT-medium 
Tryptone 16 g/l 
Yeast Extract 10 g/l 
NaCl 5 g/l 
 
SOC-medium 
Tryptone 20 g/l 
Yeast Extract 5 g/l 
NaCl 0.5 g/l 
KCl 2.5 mM 
MgCl2 20 mM 
Glucose 20 mM 
 
Plasmid vectors 
• pET30a (5422 bp): prokaryotic expression vector. 
The plasmid enabled the production of a tagged recombinant protein exploiting a 6-
His Tag on C-terminal and N-terminal tails. This vector carries a gene for 
kanamycine resistance. 
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• pET11d (5674 bp): prokaryotic expression vector. 
The plasmid carries a β-lactamase gene for ampicillin resistance. 
• pHEN2 (4522 bp): phagemid vector derived from pUC119. 
Upstream of the cloning site a sequence coding for the pelB signal peptide deriving 
from the gene coding for the pectate lyase of Erwinia carotovora) leads the 
periplasmic secretion of a polypeptide coded by an in-frame sequence in the multi-
cloning site; downstream of the polylinker there is the sequence for a c-myc peptide 
tag. The plasmid carries a β-lactamase gene for ampicillin resistance. 
Preparation and transformation of competent E. Coli cells 
The strains of Escherichia coli utilized for the molecular cloning and for protein 
expression are made competent to transformation by plasmid DNA following treatment 
with RF1/RF2 solutions (Tab. 1). 
A single colony is picked and used to start a 10 ml culture and grown o.n. at 37 °C with 
shaking. Few (1-2) ml of the overnight culture is then used to start a 50 ml culture then 
grown to OD600 = 0.3-0.4 at 25°C with shaking. 
The bacterial culture is then kept on ice for 10 minutes, after which it is centrifuged at 
5000 rpm, 15 minutes at 4 °C. Always keeping the cells at ice temperature, they are 
recovered and resuspended in 18.6 ml of sterile, ice-cold RF1 solution. After 15 minutes 
of incubation on ice the suspension is centrifuged at 5000 rpm, 15 minutes at 4 °C. The 
supernatant is removed and the bacterial pellet is resuspended in 4.5 ml of a sterile, ice-
cold RF2 solution. Cells are finally dispensed in aliquots, frozen in dry ice and kept at -
80 °C. 
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Table 1. RF1/RF2 solutions 
RF1 solution Concentration 
RbCl 100 mM 
MnCl2 50 mM 
CH3COOK 30 mM 
CaCl2 10 mM 
Glycerol 12% 
Adjust to pH 5.8 with glacial acetic acid 
RF2 solution  
MOPS 10 mM 
RbCl 10 mM 
CaCl2 75 mM 
Glycerol 12% 
Adjust to pH 6.8 with NaOH 
 
A 30 µl aliquot of competent cells are thawed on ice and mixed into a sterile tube with 5-10 
ng of plasmid DNA; in case of transformation with a ligation, 4 µl of the reaction
 
are used. 
The mixture is gently flicked and kept on ice for 30 minutes. Afterwards a heat shock is 
carried out by dipping the tube for 45 seconds in a 42°C water bath, followed by 2 minute 
incubation on ice. Eighty µl of SOC medium (without antibiotics) is then added to the tube 
which is then incubated 1 hour at 37 °C with shaking. The total amount of transformation is 
then plated on agar plates supplemented with the appropriate selective agent. Plates are 
incubated inverted at 37 °C and grown o.n. 
Human cell lines 
• SW780: human cell line of urinary bladder carcinoma; 
• PC-3: human cell line of prostate carcinoma established from the bone marrow 
metastasis; 
• LNCaP: human cell line of prostate carcinoma established from lymph node 
metastasis; 
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• DU145: human cell line of prostate carcinoma; 
• HEK 293: human embryonic kidney cell line; 
• MDCK: canine cell line of kidney; 
• Anti PSCA hybridoma: the hybridoma clone was derived from spleen lymphocytes 
of a mouse previously immunized with recombinant hPSCA; the myeloma cell line 
used in the fusion was NS-1. 
 
All cell lines are grown in flasks at 37 °C, 5% CO2, using the following medium: RPMI 
1640 medium (with 40 mg/l folic acid, 2 g/l NaHCO3) (Biochromag) and DMEM (with 
1000 or 4500 mg/l glucose) (Sigma) supplemented with 10% Fetal Calf Serum (FCS), 2 
mM L-Glutamine, 10 mM Hepes and penicillin-streptomycin 100 U/ml. 
All supplements are added into the medium after sterilization through 0.22 µm filters. 
Transfection of human cell lines 
hPSCA transfected PC-3, LNCaP, HEK 293 cell lines were obtained by transfection 
with the linearized plasmid hPSCA-pcDNA3.1 according to the following protocol: 
cells are plated in a 6 wells plate and grown until 50% confluent. Five µl of lipids are 
added to 250 µl of OPTIMEM and 2.5 µg of DNA to 250 µl of OPTIMEM. The two 
solutions are combined to form DNA complex and incubated for 30 minutes at room 
temperature. Cell medium is replaced with 500 µl of fresh medium plus 500 µl of DNA 
complex. The following day new fresh medium is added to the cells. To select 
transfected cells the antibiotic is added to the medium two days after transfection. 
hPSCA transfected MDCK cell line was obtained by transfection using the circular 
plasmid hPSCA-pcDNA3.1 according to the following protocol: cells are plated in a 10 
cm plate and grown until 30% confluent. Medium is replaced with growth medium plus 
Polybrene (30 µg) and DNA (1-10 µg). Cells are incubated for 10 hours at 37°C, 5% 
CO2 with gentle rocking every 2 hours. DMSO is diluted in growth medium and added 
for 5 min at room temperature to the DNA/Polybrene solution so that DMSO final 
concentration is 30%. The medium is aspirated; cells are washed twice with PBS and 
incubated in growth medium alone. 
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The selections of transfected cells were performed using G418 antibiotic at different 
concentrations for each cell line. 
Molecular biology techniques 
RNA extraction from anti PSCA hybridoma cells 
Six x 106 cells of the anti-PSCA hybridoma are collected by centrifugation (5 minutes, 150 
x g, 5 °C) and washed in physiologic solution. The cell pellet is then homogenized by 
resuspension in 1 ml of Trizol (TRIzol Reagent – Life Technologies, Gibco BRL) and 
incubated five minutes at room temperature. Two hundred µl of chloroform are added and, 
after a vigorous mix, incubated 3 minutes at RT. The aqueous phase containing the RNA is 
separated from the organic phase after centrifugation at 10000 rpm for 15 minutes at 4°C in 
minifuge. RNA is precipitated by addition of 500 µl isopropanol, followed by mixing and 
10 minutes incubation at 4 °C. After a wash in 75% ethanol, the RNA pellet is air-dried and 
finally resuspended in 25 µl RNAse-free H2O. Total RNA is quantified by 
spectrophotometry: 1 unit at OD260 corresponds to an RNA concentration of 40 µg/ml. 
cDNA synthesis 
Reverse transcription to cDNA is obtained using SuperScriptTM First-Strand Synthesis 
System for RT-PCR kit (Invitrogen) following the manufacturer’s instructions. 
Before performing the amplification of the fragments of interest, the quality of the cDNA is 
assessed through a polymerase-chain-reaction (PCR) test with a couple of primers designed 
for the amplification of ribonucleoprotein S15. 
 
Cycling programme: 
 
 
 
 
1 µl of cDNA is used as a template in a 25 µl reaction including a couple of primers (S15 
fw and S15 rev) at a final concentration of 0.2 µM each, dNTPs (Invitrogen) at a 
concentration of 0.2 mM each, 1 unit of Phusion DNA polymerase (Finnzyme) and 2.5 µl 
98°C    30 sec 
 
98°C    10 sec 
 
56°C    30 sec 30 cycles 
72°C    45 sec 
 
72°C    7 min 
 
4°C      
 
end 
 
Materials and Methods 
40 
 
of 10x buffer (Finnzyme) providing a final Mg2+ concentration of 2 mM. 
Amplification of the sequences coding for variable domains of heavy 
and light chains 
To select the appropriate couple of primers for the amplification of fragments coding for the 
variable regions of heavy and light chains (VH and Vκ, respectively) of the anti-PSCA 
hybridoma clone, a panel of 25 forward and 4 reverse primers are considered for each 
variable domain (25 VH forward primers and 4 JH reverse primers; 25 Vκ forward primers 
and 4 Jκ reverse primers). Forward primers were designed based on highly conserved 
sequences at the 5’-end of DNA fragments for VH and VL domains from several families of 
murine immunoglobulins; reverse primers were instead inferred from the J regions located 
at the 3’-end of VH and VL DNA regions.  
Each forward primer is tested in a PCR reaction that includes a mix of the four reverse 
primers. Once the best forward primer has been thus selected, it is used in four individual 
PCR reactions, each with a single reverse primer. The forward/reverse primers pair 
identified as the most appropriate for amplification are then re-designed as modified 
versions with suitable restriction enzymes. 
The sequence coding for the Vκ region of our anti-PSCA monoclonal antibody was PCR-
amplified using the primers 5’ Vκ 318 (Apal I) and 3’ Jκ 491 (Not I), which introduce Apal I 
and Not I restriction sites, respectively; the VH fragment was amplified with primers 5’ VH 
348 (Sfi I) and 3’ JH 354 (Xho I), introducing Sfi I and Xho I sites. 
0.4 µl of cDNA is used as a template in each 20 µl PCR reaction, along with 0.4 µM of 
each primer, 0.2 mM of each dNTP (Invitrogen), 0.4 µl of Phusion DNA polymerase 
(Finnzyme) and 2 µl 10 x buffer, providing a final Mg2+ concentration of 2 mM. 
 
 Cycling programme: 
 
 
 
 
 
85°C 2 min 
 
94°C    2 min 
 
94°C    1 min 
 
55°C    1 min 30 cycles 
72°C    1 min 
 
72°C    10 min 
 
4°C      
 
end 
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Amplification of the sequence coding for the whole scFv 
The sequence coding for the whole scFv antibody is amplified using primers LMB3 and 
pHENSeq from the pHEN2-based construct containing the variable regions of our anti-
PSCA mAb. 
The 50 µl PCR reaction is assembled using 3 ng of template plasmid construct, each primer 
at a 0.4 µM concentration, each dNTP (Invitrogen) at 0.2 mM, 1 µl of Phusion DNA 
polymerase (Finnzyme) and 5 µl of 10x buffer, providing a final Mg2+ concentration of 2 
mM. 
 
 Cycling programme: 
 
 
 
DNA digestion with restriction enzymes 
Enzymatic digestion of DNA was performed according to the indications provided by the 
manufacturers. Typically, in each reaction 5-10 units of enzyme are used to cut 1 µg of 
DNA. Reactions are usually incubated for 2 hours at the recommended temperature. In Tab. 
2 are shown the restriction enzymes used. 
 
Table 2. Restriction enzymes used. 
 
 
 
 
 
 
 
 
 
98°C    30 sec 
 
98°C    10 sec 
 
55°C    30 sec 30cycles 
72°C    50 sec 
 
72°C    10 min 
 
4°C      
 
end 
 
 
 
Manufacturer 
Stock 
concentration 
Nco I TaKaRa 10 U/µl 
Not I TaKaRa 10 U/µl 
Sfi I New England 10 U/µl 
Xho I Roche 10 U/µl 
Hind III Roche 10 U/µl 
Apal I New England 10 U/µl 
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Ligation 
Vectors and inserts for the preparation of all constructs were purified after agarose gel 
electrophoresis using the QIAEX II Gel Extraction kit (QIAGEN), and eventually ligated 
with T4 DNA ligase (New England). A 20 µl reaction is prepared in a tube containing 100 
ng of vector, a five-fold molar excess of insert fragment, the provided ligation buffer and 1 
µl of enzyme. The ligation is incubated 2 hours at 20°C, after which 4 µl are used for the 
transformation of E. coli cells. 
Colony-PCR screening 
For a rapid screening of E. coli colonies obtained after transformation with the ligation 
reaction, a PCR is performed directly on bacterial cells. 
Using a sterile tip, cells from a single colony are picked from the LB-agar plate and 
dissolved in 20 µl of PCR reaction mix with: 2. µl of 10x reaction buffer (Euroclone), 
dNTPs mix (0.2 mM of each dNTP, Invitrogen), forward and reverse primers (10 pmoles 
each), 1 unit of Taq DNA polymerase (Euroclone). If necessary, also 5% DMSO is 
included. 
 
 
Cycling programme: 
 
 
 
 
The PCR reactions are analysed by agarose-gel electrophoresis and staining with ethidium 
bromide. 
Plasmid DNA extraction from E. coli cultures 
Single colonies picked from LB-agar plates (or from small LB cultures for colony-PCR 
screening) are inoculated in 5 mL for small-scale preparations (miniprep), or in 50 mL for 
medium-scale preparations (midiprep) of LB broth additioned with the appropriate 
antibiotics (100 µg/ml Amp); the culture is grown o.n. at 37 °C with shaking (250 rpm) and 
cells are recovered by centrifugation (5 minutes, 10000 rpm at RT in minifuge for 
94°C    10 min 
 
95°C    1 min 
 
55°C    1 min 30 cycles 
72°C    
   2 min  
72°C    10 min 
 
4°C      
 
end 
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minipreps; 10 minutes, 4000 xg at RT for midipreps) and the bacterial pellet is processed 
using the PureLinkTM Qick Plasmid Miniprep kit (Invitrogen) for minipreps and the 
PureLinkTM HiPure Plasmid Filter Purification kit (Invitrogen) for midipreps, according to 
instructions provided by the manufacturers. Purity and concentration of plasmid DNA are 
assessed by agarose gel electrophoresis and ethidium bromide staining. 
Production and purification of recombinant PSCA 
Production of recombinant PSCA 
A single colony of E. coli BL21 (λDE3) transformed with pET30a coding for the 
recombinant human PSCA (hPSCA) is inoculated in 10 ml of LB medium, 30 µg/ml 
kanamycin, 0.1% glucose and grown o.n. at 37 °C with shaking at 250 rpm. The o.n. 
culture is used to start a 1 l culture in the same medium, 30 µg/ml kanamycin which is 
grown at 37 °C with shaking to an OD600 between 0.7 and 0.8. Expression of the 
recombinant protein is induced by addition of 1 mM IPTG into the culture and 
incubation is continued for 3 hours at 30 °C with shaking. The bulk of the induced 
culture is centrifuged 15 minutes at 5000 rpm, at 4 °C and the bacterial pellet is stored at -
20°C. 
Isolation of inclusion bodies and purification by affinity 
chromatography  
The pellet of the harvested induced culture is resuspended in 0.02 culture volume of 
Lysis Buffer (50 mM NaH2PO4, 1 M NaCl, pH 8.0) additioned with Protease Inhibitor 
(Roche), 0.1mg/ml Lysozyme (Sigma), DNase I (Roche) and 0.1 mM PMSF (Sigma). 
The suspension is incubated on ice for 30 minutes and then sonicated on ice until cells 
are lysed and the solution is no longer viscous. After centrifugation at 10000 x g, 10 
minutes at 4°C the supernatant is collected (cytoplasm) and the pellet, that is inclusion 
bodies, are washed twice with Lysis Buffer. The inclusion bodies are resuspended in 
0.015 culture medium of Denaturing Buffer (8 M urea, 100 mM sodium phosphate 
buffer, 10 mM tris HCl pH 8.0) and then incubated at room temperature (RT) for 30 
minutes. After centrifugation at 10000 x g, 10 min at RT the supernatant is collected 
and added to NiNTA resin. The incubation is performed for 1h at RT on an orbital 
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shaker. After collecting the flow-through the resin is washed in three steps with 
Denaturing Buffer at decreasing pH (8.0, 6.3, 5.9). The PSCA protein is eluted with 
Denaturing Buffer at pH 4.5. 
Refolding of PSCA from inclusion bodies 
Refolding of urea-denatured proteins from inclusion bodies is attained by multi-step dialysis 
that gradually decreases the concentration of denaturant, therefore promoting protein 
refolding. 
Tubular membranes with a 3 kDa cutoff (Carl Roth) are used. 
 
The dialysis steps are performed at 4 °C according to the following scheme:  
- Refolding Buffer with 6 M urea   (24 h) 
- Refolding Buffer with 4 M urea   (24 h) 
- Refolding Buffer with 2 M urea   (24 h) 
- Refolding Buffer with no urea   (24 h) 
- Tris 20 mM pH 8.0     (24 h) 
 
Refolding Buffer: 
TrisCl pH 8       20 mM 
L-Arginine        400 mM 
Urea                  different concentrations 
Oxidized glutathione  0.5 mM 
Reduced glutathione  5 mM 
PMSF                0.1 mM 
PSCA purification by ionic exchange 
The ionic exchange purification is performed with Vivapure Mini Spin columns 
(Vivascience) following the manufacturer’s instructions. The PSCA is eluted with 20 
mM Tris  HCl pH 8.0 containing 500 mM NaCl and finally dialyzed in PBS buffer o.n. 
at 4°C. 
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Production and purification of anti PSCA scFv 
Production of anti PSCA scFv 
A single colony of E. coli HB2151 transformed with pHEN-2 coding for the anti PSCA 
scFv is inoculated in 10 ml of 2X YT medium, 100 µg/ml ampicillin, 0.1% glucose and 
grown o.n. at 37 °C with shaking at 250 rpm. The o.n. culture is used to start a 1 l 
culture in the same medium, 100 µg/ml ampicillin, 0.1% glucose which is grown at 37 
°C with shaking to an OD600 between 0.7 and 0.8. Expression of the recombinant 
protein is induced by addition of 1 mM IPTG to the culture and incubation is continued 
for 20 hours at 26 °C with shaking. The bulk of the induced culture is centrifuged 15 
minutes at 5000 rpm, at 4 °C and the bacterial pellet is immediately processed for periplasm 
extraction. 
Extraction of periplasmic fraction 
Proteins were extracted from the periplasm by osmotic treatment by resuspending the 
bacterial pellet in 0.05 culture volume of ice-cold extraction buffer (30 mM TrisCl pH 8.0, 
20% sucrose, 1 mM EDTA). Cells were kept on ice for 1 hour and then centrifugated at 
15000 x g, 10 minutes at 4 °C. The supernatant containing the soluble periplasmic fraction 
is separated from the cell pellet. 
Purification of scFv by affinity chromatography 
The periplasm containing scFv is diluted 1:2 with 2 M urea, 10 mM Tris HCl pH 8.0, 150 
mM NaCl, 0.2 mM DTT and then added to NiNTA resin so that the binding of scFv to 
NiNTA resin occurs in weak denaturing conditions. The incubation is performed o.n. at 
4°C on an orbital shaker. After collecting the flow through the resin is washed in three 
steps with Binding Buffer with increasing concentrations of imidazole (5, 10 and 20 
mM). The scFv is eluted by adding Binding Buffer containing 250 mM imidazole. 
Finally the scFv is dialyzed in PBS buffer o.n. at 4°C. 
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Binding Buffer: 
Tris                  10 mM 
Urea  1 M 
EDTA  0.1 mM 
DTT   0.1 mM 
Imidazole       5 mM, 10 mM, 20 mM or 250 mM 
Adjust pH to 8.0 
Production and purification of scFv-PE40 immunotoxin 
Production of scFv-PE40 immunotoxin 
A single colony of E. coli BL21 (λDE3) pLysS transformed with pET11d coding for the 
scFv-PE40 immunotoxin is inoculated in 10 ml of LB medium, 100 µg/ml ampicillin, 
34 µg/ml chloramphenicol, 0.5% glucose, 0.05% MgSO4 and grown o.n. at 37 °C with 
shaking at 250 rpm. The o.n. culture is used to start a 1 l culture in the same medium 
which is grown at 37 °C with shaking to an OD600 between 0.7 and 0.8. Expression of 
the recombinant protein is induced by addition of 1 mM IPTG into the culture and 
incubation is continued for 3 hours at 37 °C with shaking. The bulk of the induced 
culture is centrifuged 15 minutes at 5000 rpm, at 4 °C and the bacterial pellet is stored at -
20°C. 
Isolation, denaturation and refolding of proteins from inclusion 
bodies 
Pellet of harvested induced culture is resuspended in 0.05 culture volume of IB Wash 
Buffer (20 mM Tris HCl pH 7.5, 10 mM EDTA, 1% Triton X-100) additioned with 
Protease Inhibitor (Roche), 0.1mg/ml Lysozyme (Sigma), DNase I (Roche) and 0.1 mM 
PMSF (Sigma). The suspension is incubated on ice for 30 minutes and then sonicated 
on ice until cells are lysed and the solution is no longer viscous. After centrifugation at 
10000 x g, 10 minutes at 4°C the supernatant is collected (cytoplasm) and the pellet, 
that is inclusion bodies, are washed twice with IB Wash Buffer and then solubilised at 5 
mg/ml in 50 mM CAPS pH 11, N-Lauroylsarcosine 1.2% and 1 mM DTT for 15 min at 
Materials and Methods 
47 
 
RT. After centrifugation at 10000 x g, 10 min at RT the supernatant is collected and the 
refolding of denatured proteins is attained by multi-step dialysis. 
The dialysis steps are performed at 4 °C according to the following scheme:  
 
- Refolding Buffer 1 with 0.1 mM DTT  (20 h) 
- Refolding Buffer 1 with 0.1 mM DTT  (8 h) 
- Refolding Buffer 1 with no DTT   (20 h) 
- Refolding Buffer 1 with no DTT   (8 h) 
- Refolding Buffer 2     (24 h) 
- Sodium phosphate buffer 5 mM pH 6.5  (24 h) 
  
Refolding Buffer 1: 
TrisCl pH 8.5      20 mM 
PMSF                0.1 mM 
 
Refolding Buffer 2: 
TrisCl pH 8.5      20 mM 
L-Arginine        400 mM 
Oxidized glutathione  0.5 mM 
Reduced glutathione  5 mM 
PMSF                0.1 mM 
Purification of scFv-PE40 immunotoxin 
Purification was achieved by a first step of gel filtration on a TSK3000 SW with 20 mM 
Tris, 3.4 mM EDTA, pH 7.4. Protein identification was checked by Western Blot. 
Fractions containing scFv-PE40 were collected and then subjected to a second 
purification step by anion-exchange chromatography (QAE column) with a buffer 
containg 20 mM Tris, 3.4 mM EDTA, pH 7.4 and linear gradient of NaCl from 0 mM to 
500 mM. 
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Western Blot 
Proteins separated by SDS-PAGE are blotted on nitrocellulose membranes (Trans-Blot 
transfer Medium, BioRad) following the manufacturer’s indications. The 
polyacrilamide gel and nitrocellulose membrane are assembled as a sandwich in a Mini 
Trans-Blot Electrophoretic Transfer Cell (BioRad) according to the manufacturer’s 
instructions, and a tension of 100 V is applied for 1 hour. 
Subsequently nitrocellulose membrane is incubated o.n. at 4 °C in blocking solution 
(3% w/v powder milk in deionized H2O) under stirring. After blocking, the membrane is 
first incubated with a primary antibody recognizing a specific epitope of the protein 
analysed. This is followed by incubation with a horseradish peroxidase (HRP)-
conjugated secondary antibody that interacts with the Fc portion of the primary. Both 
antibodies are diluted in blocking solution and the membrane is rinsed twice for 5 
minutes in 0.05 % Tween-20, PBS and twice for 5 minutes in PBS after each 
incubation. Bands corresponding to the immunoselected polypeptides are finally 
detected by a chemiluminescent reaction using the ECL Western Blotting Substrate 
(Pierce), according to the manufacturer’s instructions, and visualized by development of 
a photographic plate (Hyperfilm MP High performance autoradiography film - 
Amersham Biosciences). 
Production of anti PSCA monoclonal antibodies 
Monoclonal antibodies against PSCA were obtained by immunization of Balb/c mice 
with recombinant PSCA protein purified from bacteria. Polyclonal hybridomas were 
created following Khöler-Milstein protocol and PSCA-reactive polyclonal hybridomas 
were identified by ELISA and flow cytometry. Positive polyclonal hybridomas were 
adapted to growth in complete RPMI cell medium and then cloned by limiting dilution 
protocol. Monoclonal hybridomas were re-analyzed for the ability to recognize PSCA 
protein. mAbs were purified from hybridoma supernatants using the affinity 
chromatography on sepharose-protein G column. 
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Generation of anti PSCA mAb-RTA chemical immunotoxin 
Anti PSCA mAb was derivatized with the heterobifunctional cross-linker SPDP which 
reacts with mAb amino groups introducing a dithiopyridylgroup. After derivatization 
the mAb contained 1.5 sulphidryl group/mAb molecule, on average. Anti PSCA mAb-
SPDP molecule was conjugated via a reducible disulphide bond to the RTA toxin. The 
obtained anti PSCA mAb-RTA IT was separated from unconjugated RTA by gel 
filtration chromatography on TSK 3000 SW column with 5 mM sodium phosphate 
buffer, 50 mM NaCl pH 7.4. A further purification from unconjugated mAb was 
achieved by an affinity chromatography passage on Affi Blue gel column with 5 mM 
sodium phosphate buffer, 50 mM NaCl pH 7.4 and the elutions were performed with the 
same buffer containing 1 M NaCl. Fractions containing the IT, as identified by SDS-
PAGE and Western Blot analyses, were concentrated with Centricon-10 and dialysed in 
PBS buffer. The IT concentration was determined evaluating absorbance at 280 nm and 
confirmed with BCA method. 
Cells fixation by paraformaldehyde 
Cells grown on a 96 wells plate were fixed with 2% paraformaldehyde, 2% sucrose in 
PBS for 5 min at RT. After five washings with 0.001% phenol red in PBS buffer the 
neutralization was performed by incubation with 0.1 M glycine in PBS phenol red 
buffer for 10 min at RT.  After five washings with PBS phenol red fixed cells were 
stored with 1% BSA, 0.02% NaN3, 0.001% phenol red in PBS at 4°C. 
ELISA 
The ELISA assay was performed on fixed cells (see above) or on recombinant PSCA. The 
PSCA recombinant antigen was diluted at 2 µg/ml in PBS buffer and 50 µl/well were used to 
sensitize a 96-well plate (Maxisorp, Nunc). After incubation o.n. at 4°C, one wash was made 
with PBS and wells were quenched by addition of 200 µl/well blocking solution (3% w/v BSA 
in PBS) and incubation for 1 hour at 37°C. After a wash with PBS, the primary antibody was 
diluted at 5 µg/ml in blocking solution and 100 µl/well were dispensed. After 2 hours 
incubation at 4°C wells were rinsed twice with 0.05% Tween-20 in PBS and twice with PBS. 
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Secondary antibody-HRP diluted in blocking solution following manufacturer’s instructions 
was dispensed at 100 µl/well and incubated for 1 hour at 4°C. After two washings with 0.05% 
Tween-20 in PBS and two washings with PBS the assay was developed by addition of 100 
µl/well TMB substrate (Sigma) and the reaction stopped with 100 µl/well 1M HCl. The plate 
was analyzed using the VERSAmax microplate reader with a 450 nm beam and subtracting the 
background absorbance at 650 nm. 
Surface Plasmon Resonance (SPR) 
In recent years, surface plasmon resonance established itself as a powerful tool for the analysis 
of antigen-antibody interaction by the direct determination of the kinetic constants of 
association (Kon) and dissociation (Koff). SPR provides a real-time measure of the affinity 
through the monitoring of variations in the refraction index determined by the formation of 
molecular complexes on the surface of a solid substrate (“chip”), on which one of the two 
partners involved in the interaction (e.g. the PSCA antigen) is immobilized. A solution 
containing the second molecular partner (e.g. the anti-PSCA mAb or the derived scFv or Fab) 
is flowed over the chip by a microinjection system. At this stage (part 3 of curve in Fig. 1) the 
instrument (Biacore, GeHealthcare) detects an increase in the number of molecular complexes, 
signalled by a hike in RU (resonance units). From this portion of the sensorgram the Kon 
constant can be desumed. Next, a wash buffer is flowed through the instrument, thus initiating 
the dissociation stage (part 4 in Fig. 1), on which the Koff constant can be calculated. It is then 
possible to obtain the overall dissociation constant of the antigen-antibody interaction: KD = 
Koff / Kon. 
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Flow cytometry 
Cells from monolayer cultures were detached with Trypsin-EDTA 0.02%, harvested, 
washed two times with PBS-BSA 0.2% and re-suspended in cold PBS-BSA 0.2% 
containing different concentration of the mAbs under study or the control ones.  
After 1 hr incubation on ice, cells were washed two times with ice-cold PBS-BSA 0.2% 
and incubated with saturating concentrations of a goat F(ab’)2 anti-mouse 
immunoglobulin (goat anti-mouse, GAM) fluorescein isothyocianate (FITC-labeled). 
Cell associated florescence was analyzed by a flow cytometer (FacsCanto, BD 
Biosciences). Because a myc tag is present at the C-terminal of the amino acid sequence 
of the scFv fragments, the cytometric analysis was also performed using mouse anti-
myc tag antibody. The percent of positive cells and the mean fluorescence intensity 
(MFI) values were considered in evaluating antigen level of expression.  
Competitive binding studies, comparing the binding properties of anti PSCA mAbs, 
were performed by analyzing the ability of anti PSCA mAbs to prevent binding of 
biotynilated clone 1 to SW780 cells; the binding of biotinylated clone 1 was detected by 
Figure 1. Sensorgram of an “antigen-antibody” interaction. 1 – Baseline (buffer flowed on the chip); 
2 – Change in the refraction index; 3 – Association stage (Kon); 4 – Dissociation stage (Koff). 
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a second labeling step carried out with FITC Avidin. Anti PSCA clone 1 was 
biotinylated with NHS-Biotin following the manifacturer’s instructions. 
Cytotoxicity assessment by thymidine incorporation 
The effect on uptake of tritiated thymidine (3H-TdR) by cells is taken as a measure of the 
growth inhibition caused by treatment with a toxin or immunotoxin. Cells are resuspended 
in standard medium (RPMI 1640, 10% FBS, 2 mM Gln) and 1.8 x 104 cells in a volume of 
90 µl are seeded in each well of 96-well plates (Greiner Bio-one). The molecules to be 
tested are dialysed in PBS, filter-sterilized through Spin-X tubes (Costar) and diluted in 
sterile PBS containing 0.2% BSA. Ten µl of differently diluted antibody and (immuno) 
toxins are finally added in each well. The plate is incubated for 36 hours at 37 °C, 5% CO2. 
Ten µl of 3H-TdR from a 1-1.2x105 cpm/ml stock in plain RPMI are added 8 hours before 
the end time, after which the plate is kept at -20 °C and thawed at RT the day after. Using a 
cell-harvester (Wesbart), the content of each well is transferred to filter paper and 
radioactivity measured using a beta counter (Wallac 1409, Pharmacia). 
Immunofluorescence  
Permeabilized cells 
Cells are grown on coverslips and after two washings with PBS are fixed with 4% 
paraformaldehyde for 1 hour at RT. Cells are washed twice with PBS and then 
incubated twice with 50 mM NH4Cl for 10 min at RT to reduce the autofluorescence of 
cells. Permeabilization is then performed by incubation with Blocking Buffer (1% BSA, 
0.5% saporin in PBS) for 30 min at RT. Cells are incubated at RT for 45 min with anti 
PSCA antibody diluted in Blocking Buffer. After 3 washings with Blocking Buffer, the 
anti mouse-Alexa 488 diluted in Blocking Buffer is added for 45 min at RT. The 
coverslips are washed twice in Blocking Buffer and twice in PBS and then mounted on 
objective glass with moviol. Samples are kept in the dark and observed by confocal 
microscopy. 
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Surface staining 
Cells are grown on coverslips and after two washings with cold PBS are incubated at 
4°C for 1 hour with anti PSCA antibody diluted in PBS. After 3 washings with cold 
PBS, the anti mouse-Alexa 488 diluted in PBS is added for 1 hour at 4°C. The 
coverslips are washed four times with cold PBS and then incubated at 37°C for 30 min 
to induce antigen internalization. Cells are then fixed with 4% paraformaldehyde for 1 
hour at 4°C and after 4 washings with PBS the coverslips are mounted on objective 
glass with moviol. Samples are kept in the dark and observed by confocal microscopy. 
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Production of recombinant PSCA 
To create new anti PSCA mAbs the project began with the generation of recombinant 
human PSCA (hPSCA) which was then used to immunize Balb/c mice. 
Total RNA was extracted from DU145 cells with Trizol buffer and specific cDNA was 
retrotranscribed. PSCA specific cDNA was then cloned using Hind III restriction sites 
in the pET30a prokaryotic expression vector; this plasmid enabled the production of a 
tagged recombinant protein exploiting a 6-His Tag on C-terminal and N-terminal tails. 
Figure 1 shows the sequence of PSCA inserted in pET30a vector. 
 
PSCAHis-Tag His-Tag
orilacI KANr
T7 promoter T7 terminator
pET 30a
Hind III Hind III
 
The construct was expressed in the BL21 (λDE3) bacterial strain. Addition of IPTG to 
the culture medium triggers the overexpression of T7 RNA polymerase, which in turn 
superinduces the transcription of the PSCA gene being placed under the control of the 
T7 promoter in pET30a. After induction with IPTG inclusion bodies (IB) were isolated 
and then solubilized in urea containing buffer, as described in Materials and Methods. 
For protein purification solubilized IB were added to NiNTA resin. Protein purification 
and identification were checked by SDS-PAGE (Fig. 2). Fractions containing PSCA 
were collected and the protein subsequently renatured by multi-step dialysis in a 
“Refolding buffer” which allows the denaturing agent (urea) to be gradually removed. 
Because some contaminats were still present, a further ionic exchange purification using 
Vivapure Mini Spin column was necessary. The protein was eluted with a Tris buffer 
Figure 1. Schematic picture of the PSCA cDNA cloned in pET30a vector using Hind III restriction 
site. 
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containing 500 mM NaCl. An SDS-PAGE analysis shows a PSCA purity of about 90-
95%; its identity was demonstrated by Western Blot (Fig. 3). 
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Figure 2. SDS-PAGE analysis of PSCA protein purified on NiNTA column.  The PSCA protein 
shows an apparent molecular weight of 25-30 kDa and the smear is likely due to the presence of urea in 
the sample. Abbreviations: M, protein size standard; W1, wash with buffer at pH 8.0; W2, wash with 
buffer at pH 6.3; W3, wash with buffer at pH 5.9; E1, E2, E3 and E4, elution steps performed with buffer 
at pH 4.5. 
Figure 3. (A) SDS-PAGE and (B) Western Blot of purified PSCA. Coomassie staining shows the 
purity of PSCA; Western Blot performed with anti PSCA antibody (Abnova), recognizing the only 
recombinant PSCA, confirm the identity of the protein and shows the presence of a small amount of 
PSCA in dimeric form. Abbreviations: M, protein size standard; P, purified PSCA. 
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Generation and characterization of new anti PSCA mAbs 
Balb/c mice were immunized with recombinant PSCA and their spleen used for 
hybridoma generation according to Khöler-Milstein protocol. After a step selection by 
ELISA with recombinant PSCA, positive hybridomas were cloned to obtain hybridoma 
cells secreting anti PSCA monoclonal antibodies (mAbs). Ten positive clones were 
obtained and mAbs secreted form hybridomas clone 1 and clone 2 were characterized.  
The binding properties of our anti-PSCA mAbs clone 1 and clone 2 to the native 
cellular antigen were characterized by flow cytometry with SW780, PSCA positive, and 
PC-3 wild type (WT), PSCA negative, cell lines. As shown in Figure 4 and Table 1, 
both our mAbs clone 1 and clone 2 are able to recognize the native form of PSCA and 
they show a MFI (Mean Fluorescence Intensity) of 554 and 425 respectively on SW780 
(PSCA+). These values are similar to the positive control (a validated anti-PSCA 
antibody clone 7F5 [Morgenroth et al., 2007]), showing a MFI of 587, and greater than 
the negative control (incubation with isotype control mAb, MFI=79). In the same 
experiment no staining was obtained on PC-3 (PSCA-) cells demonstrating the 
specificity of our mAbs. 
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Figure 4. Flow cytometry with SW780 PSCA+ and PC-3 WT PSCA- cell lines. Negative control is 
obtained with isotype control mAb; clone 7F5 is a validated anti PSCA mAb described in the literature 
[Morgenroth et al. 2007]; clone1 and clone2 are our anti PSCA mAbs; B912.1 is an anti MHC I and it is 
used as a positive control in the flow cytometry of PC-3 WT cells. FITC-A, Fluorescein Isothiocyanate-
Area. 
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SW780 
MFI 
PC-3 WT 
MFI 
Isotype control 79  189  
Anti PSCA mAb clone 7F5 587  n.d.  
Anti PSCA mAb clone1 554 224  
Anti PSCA mAb cone2  425 244  
Positive control n.d.  1926  
The IgG-isotype of our anti PSCA mAbs was determined by an ELISA assay; results 
summarized in Table 2 show that both our mAbs belong to the IgG2b subclass. 
 
 Mouse serum Neg ctr mAb clone1 mAb clone2 
IgM 2.41 0.23 0.27 0.3 
IgG1 1.5 0.3 0.29 0.27 
IgG2a 1.5 0.17 0.19 0.18 
IgG2b 1.9 0.5 1.9 2.0 
IgG3 1.51 0.22 0.21 0.22 
IgA 0.73 0.21 0.19 0.18 
We further characterized the binding properties of our mAbs in comparison with the 
reference anti-PSCA antibody clone 7F5 in order to define possible epitope shared 
during PSCA recognition. A competitive binding assay was set up using biotinylated 
mAb clone 1 and unmodified anti PSCA mAbs as competitors. Binding of biotinylated 
anti PSCA clone 1 was revealed by FITC-Avidin staining. As shown in Table 3, anti 
PSCA clone 1 and clone 2 are able to cross-inhibit the binding of each other, whereas 
the clone 7F5 is not able to inhibit their cell surface binding. 
Table 1. Binding specificity of anti PSCA mAbs analyzed by flow cytometry. Staining was measured 
considering two parameters: MFI (Mean Fluorescence Intensity) and the percentage of positive cells. 
Table 2. ELISA assay to determine the anti PSCA mAbs isotype. Mouse serum was used as a positive 
control and culture medium as a negative control. The values showed represent the adsorbance measured 
at 450nM. 
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Therefore anti PSCA mAbs clone1 and clone2 recognize the same epitope or epitopes 
that are physically or functionally associated whereas clone 7F5 recognizes a different 
epitope. 
 
Antibody MFI 
Isotype control 74 
Anti PSCA mAb clone1 biotin 188 
Anti PSCA mAb clone1 biotin + clone1 91 
Anti PSCA mAb clone1 biotin + clone2 86 
Anti PSCA mAb clone1 biotin + clone7F5 141 
To better define the binding properties of our anti PSCA mAbs, their affinity was 
assessed through the SPR technology (Surface Plasmon Resonance). This study was 
performed in collaboration with Dr.ssa Mariangela Figini, INT Milan. Recombinant 
PSCA was chemically coupled to the surface of a “sensor chip” which was then 
analyzed by the instrument (BIACORE). The anti PSCA mAbs were tested at a 
concentration of 200 nM. As shown in Figure 5 the association/dissociation curves, also 
called sensorgrams, of the two anti PSCA mAbs are comparable. It can be observed that 
the binding properties of our mAbs are very similar. Moreover, the curves demonstrate 
a fast rate of association whereas the rate of dissociation is slow; these characteristics 
led to consider our mAbs as good tools for immunotherapy. 
Table 3. Competition binding experiment performed with SW780 cells and analyzed by flow 
cytometry.  
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Sequencing of VH and Vκ regions of the two mAbs clone 1 and clone 2 showed that they 
differ only in the light chain. Because of that and because their binding characteristics 
are comparable from now on I will consider only the mAb from clone 1. 
 
The characterization of the selected anti PSCA mAb continued by carrying out a flow 
cytometric analysis with a panel of positive and negative cell lines. At the present time 
SW780 cells are the only available cell line constitutively expressing PSCA but they 
present a variable antigen expression depending on as yet unknown factors. 
For this reason PC-3, LNCaP, HEK 293 and MDCK cell lines were stably transfected 
with hPSCA-pcDNA3.1 and they showed a constant expression of PSCA. In Table 4 are 
summarized the MFI values obtained. It can be observed that the specificity of anti 
PSCA mAb is confirmed: the mAb recognizes the antigen PSCA in transfected cells but 
it does not so in mock transfected ones. 
Figure 5. Biacore analysis of the binding properties of anti PSCA mAb clone 1 and clone 2. The 
sensorgram shows the association/dissociation curves obtained by flowing 200 nM of mAb over the chip 
on which recombinant PSCA was fixed. 
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PSCA positive cell lines (MFI values) PSCA negative cell lines (MFI values)
SW780 PC-3* 
hPSCA
LNCaP* 
hPSCA
MDCK* 
hPSCA
HEK* 293 
hPSCA
DU145 PC-3 WT LNCaP WT
MDCK 
WT
HEK 293 
WT
Isotype 
control
76 65 141 191 234 173 189 51 295 170
Anti PSCA 
mAb
2168 571 3253 1057 3126 166 224 58 248 164
Positive 
control
n.d. n.d. 2833 n.d. n.d. 1354 1926 2076 n.d. 760
 
To better define the binding properties of anti PSCA mAb, its affinity was then assessed 
by flow cytometry. A fixed amount of LNCaP hPSCA or PC-3 hPSCA cells were 
stained with increasing concentrations of anti PSCA mAb followed by incubation with a 
saturating concentration of secondary mAb, commonly a FITC-labeled goat anti mouse 
antibody. Figure 6 describes the results of the cytofluorimetric analysis; anti PSCA 
mAb reaches saturation of 50% of PSCA sites at the concentration of 23 nM and 16 nM 
respectively on LNCaP hPSCA and PC-3 hPSCA. 
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Table 4. Binding specificity of anti PSCA mAb analyzed by flow cytometry with PSCA positive and 
negative cell lines. Staining was measured considering two parameters: MFI (Mean Fluorescence 
Intensity) and the percentage of positive cells. * = transfected cell lines. 
Figure 6. Binding of anti PSCA mAb on LNCaP hPSCA and PC-3 hPSCA. Cells were incubated with 
increasing concentrations of anti PSCA mAb and the signal was detected with FITC-labeled goat anti 
mouse IgG. 
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The WT cell line LNCaP is able to express the antigen PSMA, another tumor associated 
antigen. The PSMA expression is maintained in PSCA transfected LNCaP cells. In our 
laboratory a good anti PSMA mAb is available: it reaches saturation of 50% of PSMA 
sites at concentration of 8 nM, value consistent with the range of 10-7-10-11 M for 
antibodies of biological interest. For this reason we compared the binding of our mAb to 
PSCA with the binding of anti PSMA mAb to PSMA. As shown in Fig. 7 the 
concentration of anti PSCA mAb necessary to saturate 50% of antigenic sites is only 3 
fold higher than the anti PSMA mAb concentration. These data confirm the good 
binding properties of our anti PSCA mAb. 
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Anti PSCA mAb relevance for diagnosis 
It is known that differences in the glycosylation pattern of antigens exist between 
healthy and malignant tissues [Pauli et al., 2003; Jankovic and Milutinovic, 2008; 
Robbe-Messelot et al., 2009]. To verify that our antibody is able to recognize possible 
different isoforms of PSCA a Western Blot assay was performed with cell lysate of 
Figure 7. Binding of anti PSCA and anti PSMA mAbs to LNCaP hPSCA. Cells were incubated with 
increasing concentrations of anti PSCA (blue line) or anti PSMA (violet line) antibodies. Shown are the 
fitting curves obtained. 
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MDCK expressing PSCA and it was developed using our anti PSCA mAb as primary 
antibody. As shown in Figure 8 our mAb is able to recognize PSCA bounded to any 
sugars (lane F, obtained by treating the lysate with N-Glycosidase F), to hybrid sugars 
or complex glycans. In fact in the non treated total lysate (lane /) our mAb recognizes 
many bands with a molecular weight of about 25-40 kDa. When the total lysate is 
treated with endoglycosidase H (lane H) the mAb recognizes a band of about 40 kDa, 
corresponding to PSCA bounded to complex glycans, and about 22 kDa, deriving by the 
cleavage of mannose rich glycans from PSCA bounded to hybrid sugars. When the total 
lysate is treated with N-Glycosidase F the mAb recognizes a band of about 15 kDa, 
corresponding to PSCA bounded to any sugar. 
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Moreover to verify the ability of our antibody to recognize the antigen in tumor tissues 
our mAb was used as primary antibody in Western Blot performed with tissue lysates 
from patients. As shown in Figure 9 the anti PSCA mAb is able to detect the presence 
of denatured PSCA in 3 out of 3 prostate neoplastic tissue lysates and in 2 out of 3 
pancreatic neoplastic tissue lysates, whereas no signal is detected in normal tissues 
(stomach, uterus and spleen) used as negative controls. These data demonstrate the 
Figure 8. Western Blot of MDCK hPSCA cell lysates. The cell lysate is loaded without treatment (/), 
after treatment with endoglycosidase H (H), after treatment with N-Glycosidase F (F). Endoglycosidase 
H cleaves mannose rich glycans, N-Glycosidase F cleaves complex glycans. The Western Blot was 
performed using our anti PSCA antibody as primary antibody and anti mouse-HRP as secondary 
antibody. 
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specificity of the signal due to the binding of anti PSCA mAb to the antigen expressed 
in neoplastic tissues.  
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To further characterize the diagnostic potential of our anti PSCA mAb an ELISA assay 
was performed with cells fixed with 2% paraformaldehyde. Anti PSCA mAb is able to 
stain SW780 cell surface whereas no signal is detected on DU145 cell surface, a PSCA 
negative cell line (Fig. 10). The ability to identify PSCA on tumor tissues of patients 
and on fixed cells leads us to consider our mAbs a possible tool in both diagnostic (for 
instance immunohistochemistry, IHC) and therapeutic approaches. 
 
Figure 9. Recognition of PSCA in neoplastic tissues by Western Blot. (a) lanes 1, 2, 3: pancreatic 
tumor tissue lysates; 4, 5, 6 prostate tumor tissue lysates; (b) lanes 7, 8, 9: normal tissue lysates: stomach, 
spleen and uterus respectively. The Western Blot was performed using our anti PSCA mAb as primary 
antibody and anti mouse-HRP as secondary antibody. 
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Anti PSCA mAb relevance for immunotherapy 
Gu et al. [2005] described the ability of an anti PSCA mAb to induce cell death in vitro 
through a direct, Fc-independent mechanism. Shown in Figure 11 are results from the 
work by Gu et al. [2005]. For this reason we first evaluated if our anti PSCA antibody 
had cytotoxic effects by itself on a PSCA positive cell line. When PC-3 hPSCA cells are 
incubated for 36 h with anti PSCA mAb we observed no cytotoxic effect (Fig. 12). 
Therefore, our anti PSCA mAb is not able to induce cell death through a direct 
mechanism probably because our mAb binds to a different epitope from the epitope 
recognized by the anti PSCA Ab described in literature. It is therefore interesting that 
the apoptosis induction mechanism activated throught PSCA could be dissected using 
mAb to different epitopes. 
 
Figure 10. Whole mAb recognizes native PSCA by ELISA with whole fixed SW780 cells. Our anti-
PSCA mAb clone 1 recognizes native hPSCA on SW780 cells fixed with 2% paraformaldehyde. The 
ability of the mAb to recognize fixed cells could allow its use in immunohistochemistry (IHC). The 
antibody B912.1 was used as positive control because it binds to MHC I. 
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Figure 11. Anti PSCA mAb, described by Gu, leads to cell growth inhibition through a direct effect. 
LNCaP-PSCA cells were incubated with PBS or anti PSCA mAb for the indicated time. Cell proliferation 
was measured by (A) counting viable cells after Trypan Blue staining or (B) via MTT assay. (Modified 
from Gu et al., 2005). 
PC-3 hPSCA
Concentration (mol/l)
1e-16 1e-15 1e-14 1e-13 1e-12 1e-11 1e-10 1e-9 1e-8 1e-7 1e-6 1e-5
3 H
Td
R 
in
co
rp
o
ra
tio
n
 
(%
 
o
f u
n
tre
a
te
d 
co
n
tro
l)
0
10
20
30
40
50
60
70
80
90
100
110
120
 Ricin 
anti PSCA mAb
 
Figure 12.  In vitro cytotoxicity using the PC-3 hPSCA cell line. The cytotoxic effect of our anti PSCA 
mAb is compared with a potent toxin, Ricin. Shown is the percentage of 3HTdR incorporation as a 
function of concentration.  
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Because in our case the direct approach is not sufficient to kill tumor cells, my research 
was focused on the generation of immunotoxins (ITs). 
To make sure that anti PSCA mAb represents a suitable targeting molecule for the 
design of an immunotoxin, the internalization of the antibody following binding to 
PSCA on target cells was evaluated by flow cytometry. This assay was performed on 
SW780 cells and we used Trypan Blue which is able to quench about 50-60% the 
amount of surface fluorescence. All MFI values were obtained by pre-incubating cells at 
4°C with a FITC labelled antibody. “MFI sample” (see Table 5), obtained incubating 
the cells with our anti PSCA mAb, was normalized using a negative control obtained 
incubating the cells with irrelevant antibody (MFI sample/MFI negative control). In this 
experiment (Tab. 5) it can be observed that the ratio MFI sample/MFI negative control 
is 2.2 when cells are analysed immediately, it decreases to 1.07 after Trypan Blue 
treatment, but it increases again to 2.07 when cells are incubated at 37°C (to induce 
internalization) and then treated with Trypan Blue. In the last sample Trypan Blue is not 
able to quench the Ag-Ab complex fluorescence because the complex has translocated 
inside the cell. To confirm these results the same experiment was performed with 
LNCaP WT cells (PSMA+) incubated with anti PSMA-FITC Ab because the PSMA-Ab 
internalization is known [Liu et al., 1998]. Comparing the two experiments we can 
demonstrate that the anti PSCA mAb is 87% internalized after incubation at 37 °C. For 
this reason the work continued by generating chemical immunotoxins. 
 
MFI sample/ 
MFI neg ctrl  
+ 4°C 
+ 4°C + 
TB 
+4°C 
+ 37°C + TB 
% internalized 
Ab 
SW780 2.2 1.07 2.07 87% 
LNCaP WT 7.3 3.6 5.3 45% 
Table 5. Internalization assay. MFI sample/MFI negative control ratio value on SW780 or LNCaP  WT 
cells incubated with mAb at +4°C and analyzed immediately (+4°C), after treatment with Trypan Blue 
(+4°C + TB), after incubation at +37°C and treatment with Trypan Blue (+4°C + TB). Results obtained 
with SW780 cells are compared with results obtained with an anti PSMA mAb and LNCaP WT cells
(PSMA+), known to be able to internalize PSMA-Ab complexes. 
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Construction of chemical immunotoxin 
The anti PSCA mAb (whole molecule) was chemically linked to ricin A chain toxin 
(RTA) to create an anti PSCA mAb-RTA immunotoxin (IT). 
Chemically linked immunotoxin was synthesized by conjugating RTA toxin to the anti 
PSCA mAb via a disulfide bond, using the bifunctional cross-linker SPDP. After 
reduction of cysteines on RTA protein by DTT and derivatization of the mAb with 
SPDP, the cross-linking reaction of these two reagents took place for about 2 days at 
4°C; the immunotoxin obtained was then separated from unconjugated reagents by a 
first step of gel filtration chromatography. The chromatogram of Figure 13 displays a 
purification run obtained using a Bio-Rad FPLC apparatus. A second step of 
chromatographic purification on an Affi-Blue gel column allowed the removal of 
unconjugated mAbs from the selected fractions. It is mandatory to eliminate these free 
mAbs, because they could be able to compete with immunotoxin for the binding to the 
target Ag; this competition could mask the real killing efficacy of the immunotoxin in 
the cells assay. 
Coomassie-staining of a SDS-PAGE and a Western Blot (Fig. 14) confirmed effective 
binding of RTA to the mAb and the absence of free mAb and RTA in the purified 
immunotoxin. 
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Cytotoxicity of the immunotoxin 
The cytotoxic potential of the chemical immunotoxin was evaluated by checking the 
effect of increasing concentrations of the immunotoxin on the incorporation of tritiated 
thymidine (3H-TdR) by target and non-target cells. For comparison, also the anti PSCA 
Figure 13. Chromatogram of a purification run of the immunotoxin on a gel filtration column. 
Abbreviations: Ab, anti PSCA mAb; IT, anti PSCA-RTA immunotoxin 
Figure 14. (A) SDS-PAGE and (B) Western Blot performed using anti RTA antibody. 
Abbreviations: mAb, anti PSCA mAb; IT, anti PSCA-RTA immunotoxin; M, protein size standard. 
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mAb and RTA alone were tested. Cytotoxic effects were compared in terms of IC50, 
which defines the reagent concentration able to inhibit cell proliferation of about 50% 
with respect to an untreated control. The plots in Figure 15 clearly show that the 
immunotoxin can inhibit the proliferation of cells expressing the PSCA antigen, while 
the mAb has no detectable toxic activity within the range of the concentrations used. 
The immunotoxin has a more potent cytotoxic action as compared with RTA toxin 
alone: the IC50 value of the anti PSCA mAb-RTA is 100 times lower than the IC50 of the 
RTA toxin (Tab. 6). This difference is not detectable in a PSCA negative cell line: the 
IC50 value is 1x10-7 (mol/l) and 5x10-7 (mol/l) respectively, for the anti PSCA mAb-
RTA and RTA. Comparing the IC50 value of our immunotoxin after targeting PC-3 
hPSCA cells with another irrelevant anti CD5 immunotoxin, it can be observed that the 
cytotoxic effect of anti PSCA mAb-RTA is 100 fold higher than that of anti CD5 mAb-
RTA. These results signify that the greater toxicity of our immunotoxin is due to the 
specific binding of anti PSCA mAb to the PSCA antigen. 
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Figure 15. Dose-response curves obtained by treating PC-3 hPSCA and PC-3 WT cell lines with 
increasing concentrations of the molecules described in the picture. Shown is the percentage of 3HTdr 
incorporation as a function of concentration.  
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Monensin - + - +
Toxin/Immunotoxin PC-3 hPSCA
IC50 (mol/l)
PC-3 WT
IC50 (mol/l)
anti PSCA mAb-nRTA  1,3x10-9 1,2x10-10 1x10-7 1,5x10-7
nRTA 1,2x10-7 2x10-8 5x10-7 1,3x10-8
Ricin 2x10-13 4x10-14
mAb OKT9-nRTA 2x10-11 3x10-12
anti CD5 mAb-nRTA 1,2x10-7 1,3x10-8
anti PSCA mAb >10-6 >10-6
 
The carboxylic ionophore monensin is known to increase the cytotoxic activity of 
immunoconjugates [Candiani et al., 1991]. The potentiating effect is mediated by the 
enhancement of lysosomal pH and the inhibition of IT degradation [Ippoliti et al., 
1998]. For this reason we assessed the cytotoxic effects of toxins also in the presence of 
50 mM monensin. As shown in Table 6, monensin is able to enhance the cytotoxic 
effect by 10 times with all tested toxins and immunotoxins. Also in this case the 
cytotoxic effect of anti PSCA mAb-RTA is 100 fold higher than that of RTA. 
Construction of an anti PSCA scFv antibody 
Because our home-made anti PSCA antibody shows a good affinity and specificity we 
decided to generate anti PSCA scFv by cloning the variable domains of heavy (VH) and 
light (VL) chains. 
The cDNA obtained from cells of our hybridoma clone was used as a template for the 
PCR screening of an array of primers designed to amplify DNA fragments coding for 
the VH and VL. Since mouse Ig use preferentially κ light chains (1:10 ratio λ/κ), we 
employed degenerate primers for Vκ and Jκ domains only. Primers for this first 
Table 6. Values of concentrations inhibiting 50% of the maximal proliferation (IC50) for different 
molecules on positive cell line (PC-3 hPSCA) and negative cell line (PC-3 WT). Monensin is added 
(+) or not (-) to cells during the experiment at the concentration of 50 nM. 
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amplification were designed to match the leader regions of the VH and Vκ chains and 
both constant regions of heavy and light chains. Twenty-five PCR reactions were 
carried out for each V chain combining 25 different VH or Vκ murine domain forward 
primers with a mix of four JH or Jκ corresponding reverse primers, as showed in Figure 
16. The products of VH or Vκ amplifications can be visualized on a 2% agarose gel and 
are approximatly ∼350-390 bp long; in the picture it can be observed that due to the 
degeneration of primer sequences we obtain amplification products from several V 
primers. Among them, according to band intensity and low amplification background, 
we have chosen one VH and one Vκ forward primers. 
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At this point it was important to test the “joining” (J) primers separately in order to 
identify JH and Jκ ones leading to the best matching pair for heavy and light chain 
amplification.  Figure 17 shows that two JH primers and two Jκ primers, associated with 
Figure 16. Screening of forward primers for the amplification of DNA sequences coding for the 
variable domains of the anti PSCA mAb. PCR amplificates were analyzed by agarose gel 
electrophoresis. VH (A) and Vκ (B) amplifications were tested with different forward primers (lanes 1-25). 
The negative control (-) was a PCR reaction with no template. Arrows indicate amplificates from primers 
selected for further characterization. Ld = DNA Ladder.  
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the variable respective VH and Vκ, are able to amplify the V domains. Also in this case 
we have chosen the reverse primer corresponding to the single and most abundant 
amplificate. 
 
(A) JH primers
0.5 kb
0.3 kb
0.1 kb
Ld           I           II          III        IV
0.5 kb
0.3 kb
0.1 kb
I           II          III        IV       Ld
(B) Jκ primers
 
V genes obtained by PCR were sequenced using the same forward and reverse primers 
as for PCR reactions; to confirm that these sequences matched V domain of mouse Ig 
protein we compared by computer analysis our V amplified DNA using Blast NCI 
Software. 
A second amplification was carried out to insert desired restriction sites (Sfi I/Xho I and 
Apa LI/Not I for VH and Vκ respectively) to facilitate directional cloning of the VH and 
Vκ domains in pHEN-2 plasmid. Figure 18 represents a schematic picture of the 
synthesized plasmid pHEN2-anti PSCA scFv. 
 
Figure 17. Screening of reverse primers for the amplification of DNA sequences coding for the 
variable domains of the anti PSCA mAb. PCR products obtained amplifying VH region using the best 
forward primer with each of four reverse JH primers (A) and Vκ region using the best forward primer with 
each of four reverse Jκ primers (B). Arrows indicate amplificates from primers selected. Ld = DNA 
Ladder.  
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Production and purification of anti PSCA scFv antibody 
The scFv protein was produced in HB2151 E. Coli bacterial strain using the pHEN-2 
vector which contains a pelB leader sequence up-stream and c-myc and His-tag 
sequences down-stream to the scFv insert; this allows an easier detection and 
purification of the protein.  
The level of scFv synthesis in HB2151 was first assessed in small-scale cultures. The 
intracellular localization and solubility of the single-chain antibody expressed in 
HB2151 E. coli was investigated with the intention of maximizing the share of induced 
protein being stored in the periplasmic compartment, which normally allows the 
recovery of more appropriately folded and soluble polypeptides. Different conditions 
for protein induction were tested (Table 7). In each case the cell extracts, corresponding 
to the soluble cytoplasmic and periplasmic fractions and to the insoluble protein 
fraction, were prepared and analyzed by Western Blot using an anti His Tag antibody 
(Fig. 19). The band of size about 30 kDa represented scFv protein. Finally we decided 
to grow bacteria in 2X YT medium added with glucose 0.1% and ampicillin 100µg/ml 
and induced with 1 mM IPTG for 20h at 26°C. 
 
 
 
Figure 18. Schematic picture of the plasmid pHEN2-anti PSCA scFv.
Results 
77 
 
Induction 
Temperature 
Induction 
duration 
37°C 
3 h 
20 h 
30°C 
3 h 
20 h 
26°C 
3 h 
20 h 
IB    C   Prip IB   C   Prip
26°C 30°C
kDa
26
55
95
34
43
72
scFv
 
To purify the scFv I have tried different methodologies (ion exchange and affinity 
chromatography, gel filtration) using cytoplasmic, periplasmic or insoluble protein 
fractions (data not shown). The method supplying the highest yield and level of 
purification was the purification from the periplasmic fraction by affinity 
chromatography. The binding of scFv to NiNTA resin, which is able to bind 6-His 
tagged proteins, occurred in weak denaturing conditions (see Materials and Methods). 
Table 7. Table summarizing the induction conditions tested with the anti PSCA scFv.
Figure 19. Western Blot of bacterial fractions. Each fraction was obtained after induction with 1 mM 
IPTG for 20 h at 26°C or 30°C. The band at about 30 kDa represents our scFv protein. The Western Blot 
was performed with anti His Tag antibody. Abbreviations: IB, inclusion bodies; C, cytoplasmic soluble 
fraction; Perip, periplasmic soluble fraction. 
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The periplasmic fraction was added to NiNTA resin and then incubated o.n. at 4°C on 
an orbital shaker. After sequential washings with Tris 20mM pH=8.0 additioned with 
increasing concentrations of imidazole (from 0 to 20 mM), the scFv protein was eluted 
from the resin with a Tris buffer containing 250 mM imidazole. Protein purification and 
identification were checked by SDS-PAGE and by Western Blot (Fig. 20). The band of 
size between 28 and 36 kDa represented scFv protein. 
E1    E2     E3 E4    E5   M kDa
17
55
28
36
72
Perip  FT     E1     E2      E3 E4     E5   
A B
 
Anti PSCA scFv antibody characterization 
Functional and binding properties of anti PSCA scFv were investigated by flow 
cytometry and by ELISA using anti PSCA whole mAb as control. 
The immunoenzymatic assay performed on recombinant PSCA confirmed that the 
antibody fragment produced in E. Coli retains the binding specificity of the parental anti 
PSCA mAb, with nearly no background and no reactivity on an unrelated protein (BSA) 
(Fig. 21).  The signal obtained with scFv is lower than that obtained with the whole 
mAb. This difference can be due to the monovalent binding property of the scFv in 
comparison with the divalent binding of the whole mAb. In order to create a scFv in 
divalent form scFv was preincubated with anti myc antibody for 1h at room 
Figure 20. (A) SDS-PAGE analysis and (B) Western Blot of anti PSCA scFv protein purified on 
NiNTA column. Coomassie staining shows the purity of anti PSCA scFv; Western Blot performed with 
anti His Tag antibody confirms the identity of the protein. Abbreviations: M, protein size standard; Perip, 
periplasmic fraction of induced bacterial culture; FT, flow through of the NiNTA resin; E1, E2, E3, E4 
and E5, elution steps performed with Tris buffer containing 250 mM Imidazole. 
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temperature. In this way two scFv monomers are cross linked via an antibody-mediated 
myc-Tag interaction. Staining of cells with scFv in divalent form is similar to that 
obtained with the whole mAb. 
0
0,5
1
1,5
2
2,5
3
3,5
4
4,5
mAb scFv scFv +anti-
myc
neg ctr
PSCA
BSA
 
The flow cytometry analysis (Fig. 22, Tab. 8), performed with positive cell lines 
(SW780, LNCaP hPSCA) and negative cell lines (PC-3 WT, LNCaP WT), confirmed 
the interaction of our scFv with the PSCA antigen expressed on the surface of target 
cells. 
When assayed on LNCaP hPSCA cells the scFv shows a MFI value of 834 whereas the 
MFI of the negative control is 369; the mAb (whole molecule) specifically detects 
PSCA+ cells with a MFI of 4401. Also in this case when the scFv is preincubated with 
an anti myc antibody the staining increases (MFI value of 4010) and it reaches a value 
close to that obtained with whole mAb. 
 
Figure 21. ELISA of recombinant PSCA. Anti PSCA scFv shows a specific binding to recombinant 
PSCA. The scFv staining is lower than that of the mAb. Staining of scFv preicubated with anti myc 
antibody is similar to that obtained with the whole mAb.  
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(A) Isotype control (B) Anti PSCA scFv (C) Anti PSCA scFv +anti-myc (D) Anti PSCA mAb
LNCaP hPSCA cell line
 
PSCA positive cell lines 
MFI values
PSCA negative cell lines 
MFI values
SW780 LNCaP hPSCA PC-3 WT LNCaP WT
Isotype control 64 369 111 184
Anti PSCA scFv 382 834 142 167
Anti PSCA scFv + anti-myc 931 4010 124 n.d.
Anti PSCA mAb 2662 4401 133 58
Positive control n.d. n.d. 525 2076
 
To better define the binding properties of the single chain fragment its kinetic 
parameters were determined by Biacore assay. Thanks to a collaboration with Dr.ssa 
Mariangela Figini, INT Milan, the dissociation constant (KD) of the interaction between 
our scFv and recombinant PSCA was determinated by the SPR technology (Surface 
Plasmon Resonance). Association/dissociation curves were obtained by flowing 
different diluitions of the scFv on chips coated with a fixed amount of recombinant 
PSCA (Fig. 23). From this curves the following kinetic constants were deduced: kon = 
1.16 x 105 (1/Ms), koff = 2.65 x 10-3 (1/s). The resulting KD (koff / kon) is 2.29 x 10-8 M. 
This value is consistent with a KD of 1.41 x 10-8 M determined for the Fab derived from 
Figure 22. Flow cytometry analysis of LNCaP hPSCA cells. (A) Negative control. (B) Binding of anti 
PSCA scFv(C) Binding of anti PSCA scFv in divalent format obtained by preincubating it with anty myc 
antibody. (D) Binding of mAb anti PSCA (whole antibody). 
Table 8. Binding specificity of anti PSCA scFv analyzed by flow cytometry with PSCA positive and 
negative cell lines. 
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our anti PSCA mAb. This means that the recombinant fragment scFv produced in E. 
Coli and purified from the periplasm maintains the same binding properties as the 
parental Fab. 
Moreover we compared the association/dissociation curves obtained by injecting 200 
nM of anti PSCA scFv, Fab or whole mAb on the same PSCA coated chip (Fig. 24). As 
expected the scFv and Fab curves are comparable whereas the mAb shows a greater 
affinity. 
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Figure 23. Biacore analysis to determine scFv kinetic parameters. The association/dissociation curves 
were obtained by flowing different dilutions of the scFv over a PSCA coated chip. 
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Generation of a recombinant immunotoxin 
PE40 toxin is known to follow a translocation route similar to RTA [Falnes and 
Sandvig, 2000]. Moreover PE40 toxin bears in its sequence a cleavable site (5’ to the 
enzymatic domain), which, once recognized by furin or furin like-proteases, allows the 
intracellular separation of the vehicle from the toxic moiety of the IT. If the toxin 
moiety is not released from the carrier molecule, the toxin is not able to translocate in 
the cytosol and it cannot intoxicate the cells. To create the fusion IT anti PSCA scFv-
PE40 we used a vector available in the laboratory: a pET 11d plasmid carrying the PE40 
toxin sequence. The scFv sequence was modified by PCR to add a Hind III site at 3’. As 
shown in Figure 25 the PCR product is a band of about 800-900 bp; this DNA was 
cloned in pET 11d plasmid with Nco I/Hind III restriction sites; a scheme of the plasmid 
is displayed in Figure 26. 
 
Figure 24. Biacore analysis of the binding properties of anti PSCA whole antibody and its 
fragments.  
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furin or furin-like 
proteases
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A small-scale expression of the IT in BL21 (λDE3) pLysS E. Coli yielded an induced 
protein of approximately 70kDa, as visualized by Western Blot (Fig. 27), consistent 
with the expected size for a fusion between the scFv (30 kDa) and PE40 (40 kDa). 
 
Figure 25. PCR product obtained by amplifying the anti PSCA scFv sequence. The arrow indicates 
the amplificate of about 800-900 bp (lane 1). Ld = DNA Ladder. 
Figure 26. Schematic picture of the plasmid pET11d-anti PSCA scFv-PE40.
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To maximize the yield of the immunotoxin the bacteria were induced with 1 mM IPTG 
for different times (3 h, 5 h, 20 h) at different temperatures (30-37°C). The amount of 
produced protein and its site of subcellular storage (inclusion bodies, cytoplasm) were 
analyzed by Western Blot using an anti PE antibody; with an incubation time of 3h at 
37°C the highest amount of protein was detected in the inclusion bodies fraction (Fig. 
28). Moreover it was observed that the amount of produced immunotoxin increases 
when bacteria are harvested just before induction and then induced in LB medium 
lacking glucose (Fig. 29). Also in this case the immunotoxin is detected in the inclusion 
bodies fraction. 
Figure 27. Western Blot of total bacterial lysate. The Western Blot was performed using an anti PE 
antibody. The same amount of total protein was loaded form non induced (n.i.) and induced (i.) bacterial 
cultures. The band at about 70 kDa represents the immunotoxin (IT). 
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Before beginning protein purifications, proteins located in inclusion bodies were 
solubilized and refolded as described in Materials and Methods. As shown in Figure 30, 
during the refolding steps the immunotoxin aggregates generating multimers with a 
Figure 28. Western Blot of bacterial fractions using anti PE antibody. Each fraction is obtained after 
induction with 1mM IPTG at 37°C for 0h (n.i.), 3h or 5h. The band at about 70 kDa represents the anti 
PSCA scFv-PE40. Abbreviations: IB, inclusion bodies; C, cytoplasmic soluble fraction. 
Figure 29. (A) SDS-PAGE and (B) Western Blot of bacterial fractions. A bacterial culture was 
induced with IPTG 1 mM at 37°C for 3 h in LB medium added (+) or lacking (-) of glucose. The Western 
Blot was performed with an anti PE antibody. Abbreviations: IB, inclusion bodies; C, cytoplasmic soluble 
fraction; M, protein size standard. 
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molecular weight greater than 170 kDa. The refolding procedure is currently being 
optimized. 
 
M   D     I    II   III  IV    V   VI
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95
34
43
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kDa
170
 
An ELISA assay with recombinant PSCA provided a qualitative indication of binding 
selectivity for the refolded inclusion bodies containing scFv-PE40 (Fig. 31). 
 
Anti PSCA mAb Anti PSCA scFv-PE40 Neg ctr
 
Figure 30. SDS-PAGE of samples taken at different steps of the refolding procedure. Abbreviations:
M, protein size standard; D, denatured inclusion bodies; I-VI, inclusion bodies during refolding dialysis. 
Figure 31. ELISA assay performed with recombinant PSCA. A whole refolded IB extract containing 
scFv-PE40 shows a specific binding on recombinant PSCA. 
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The whole refolded IB were then assessed by flow cytometry on positive (LNCaP 
hPSCA) and negative (LNCaP WT) cell lines (Fig. 32). When assayed on LNCaP 
hPSCA cells the refolded IB showed a MFI value of 1100, 5 fold higher than that of 
Isotype control (MFI = 222). Whereas when assayed on LNCaP WT cells the refolded 
IB showed a MFI value of 441, 1.6 fold higher than that Isotype control (MFI = 269). 
This low staining on negative cells is due to non specific binding of contaminants 
present in the exctract. This assay confirmed that the interaction of scFv with the PSCA 
antigen expressed on the surface of target cells is preserved after fusion to PE40 toxin. 
 
(A) Isotype control (B) Anti PSCA scFv-PE40 (C) Anti PSCA mAb
LNCaP hPSCA cell line
(D) Isotype control (E) Anti PSCA scFv-PE40 (F) Positive control
LNCaP WT cell line
 
Figure 32. Flow cytometry on LNCaP hPSCA cells (A-B-C) and LNCaP WT (D-E-F). (A-D) Isotype 
control is used as negative control. (B-E) Binding of whole refolded IB extract containing scFv-PE40
immunotoxin. (C) Binding of anti PSCA whole antibody and (F) anti MHC I antibody were used as 
positive control. 
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Different purification methods were tested to obtain the highest amount and level of 
purity of immunotoxin. In my hands the best purification protocol consists in the 
purification from refolded inclusion bodies by a first step of gel filtration. Protein 
purification and identification were checked by Western Blot (Fig. 33). Fractions 
containing scFv-PE40 were collected and, because of a low protein pI (5.3), were then 
subjected to a second purification step through adsorption on an anion-exchange resin 
(QAE). 
This protocol allows to obtain scFv-PE40 with no contaminants but it does not separate 
immunotoxin monomers from multimeric forms (Fig. 34). To overcome this problem 
and also to increase the yield of purified protein the purification protocol is still being 
optimized. 
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Figure 33. Western Blot of fractions obtained from the first chromatographic separation of scFv-
PE40 on gel filtration. The Western Blot was performed with anti PE antibody. Abbreviations: M, 
protein size standard; 14-27, fractions collected from gel filtration. 
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Generation of a cellular model of polarized epithelial tissue 
The PSCA distribution and trafficking processes post-internalization could be different 
in polarized cells both normal and tumoral. To study the efficacy of anti PSCA 
immunotoxins in polarized cells a cellular model of polarized epithelial tissue 
expressing PSCA was generated. Madin-Darby canine kidney (MDCK) cells are a well 
differentiated cell line with tight junctions that form polarized monolayers in culture 
that closely resemble epithelial tissue. For this purpose MDCK cells were transfected 
with hPSCA-pcDNA3.1 plasmid and immunofluorescences were permormed using our 
anti PSCA mAb.  
Immunofluorescence on permeabilized cells (Fig. 35A) showed the distribution of 
PSCA in the whole molecule: it localizes on the cell surface, both apical and basolateral 
membrane, and in its closeness. When the immunofluorescence is performed on non 
permeabilized cells the anti PSCA antibody can reach only the apical membrane 
because the tight junctions do not permit the mAb to reach the basolateral membrane 
(Fig. 35B). In this case we can appreciate that PSCA is distributed on all apical 
membrane. A preliminary study on PSCA routing is shown in Fig. 35C where cells, 
monomer
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Figure 34. SDS-PAGE of purified immunotoxin. The scFv-PE40 (IT) is present as monomer (molecular 
weight of about 70 kDa) and multimer (molecular weight more than 170 kDa). Abbreviations: M, protein 
size standard. 
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after anti PSCA mAb binding, are incubated at 37°C for 1 h and then subjected to the 
same conditions as previous sample. It is possible to observe that PSCA from the apical 
membrane can reach the basolateral membrane through small vescicules represented as 
small green dots in the middle of the cell. This cell model could be used to study the 
PSCA routing in order to find the best toxic portion to create potent immunotoxin and 
also to study the cellular intoxication adding immunotoxins to apical or basolater or 
both membranes. 
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Figure 35. Immunofluorescence on MDCK hPSCA cells stained with anti PSCA mAb. (A) To 
evidence PSCA distribution in the whole cells, after fixation and permeabilization MDCK were incubated
with anti PSCA antibody at 4°C. (B) To investigate the distribution of PSCA on the sole apical 
membrane, cells were incubated with anti PSCA mAb at 4°C and then fixed. (C) The internalization of 
PSCA from the apical membrane is obtained by staining cells with anti PSCA mAb at 4°C and, after 
washing, incubating them at 37°C for 30 min. PSCA from the apical membrane can reach the basolateral 
membrane by vescicules. 
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Cancer is the second leading cause of human death next to coronary disease. 
Worldwide, millions of people die from cancer every year and deaths generally are on 
the rise. Conventional therapies, like surgery, radiotherapy and chemotherapy, are not 
always sufficient to eliminate the tumor and the possible metastases; moreover these 
therapies are responsible of many side effects. For this reason there is an urgent need for 
new treatments strategies, the most promising one is probably immunotherapy. 
In this context prostate stem cell antigen (PSCA) represents an ideal choice for 
immunotherapy because it is highly expressed by a large proportion of human prostate, 
pancreatic and bladder tumors, including metastatic and hormone-refractory prostate 
cancers, but has limited expression in normal tissues [Gu et al., 2000; Wente et al., 
2005; Elsamman et al., 2006]. This restricted expression profile of PSCA also makes it 
a potential diagnostic and prognostic biomarker for PSCA expressing cancers. 
This project started with the generation of anti PSCA monoclonal antibodies (mAbs) 
obtained by mice immunization with recombinant PSCA and subsequent hybridoma 
generation according to Köhler-Milstein protocol. Ten clones were able to recognize the 
recombinant PSCA in the ELISA assay and among them the two having highest affinity 
for the antigen were chosen: clone 1 and clone 2. As the mice were immunized with the 
recombinant PSCA, it was important to evaluate if the two mAbs were able to recognize 
the native PSCA expressed on the cell surface. For this reason the mAbs were analyzed 
by flow cytometry performed with SW780 (PSCA+) and PC-3 WT (PSCA-) cells. The 
MFI values obtained with our mAbs were similar and comparable to the clone 7F5, a 
validated anti PSCA antibody described in literature [Morgenroth et al., 2007]. These 
results demonstrate that our mAbs are able to recognize the native PSCA with a good 
specificity.  
The research continued with the characterization of the two mAbs. 
It is interesting to observe that the two mAbs have similar characteristics. The ELISA 
assay determinated that clone 1 and clone 2 belong to the same subclass: IgG2b. 
Moreover in a binding competition experiment, performed with SW780 and analyzed 
by flow cytometry, the two mAbs were able to cross inhibit the binding of each other. 
From this experiment it could be supposed that the two mAbs recognize the same or at 
least partially overlapping epitopes on the antigen PSCA. Thanks to the Surface 
Plasmon Resonance technology, which studies the affinity of the mAbs for the PSCA, it 
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was possible to observe that the binding properties of clone 1 and clone 2 are similar. In 
fact the association/dissociation curves are comparable and they show a fast rate of 
association and a slow rate of dissociation demonstrating that the mAbs assessed have a 
good affinity for PSCA. Subsequently the variable region of the light (VL) and heavy 
(VH) chain of the two mAbs were cloned. The comparison of the nucleotidic and 
deduced aminoacidic sequences showed that the two mAbs have the same VH but 
different VL. Kabat and Wu [1991] examined a large database of amino acid sequences 
of antibodies of various specificities and they found that for many antibodies the 
specificity is due to the VH region and in particular to the CDRH3 (Complementary-
Determining Region 3 of the heavy chain). Indeed, they found that many antibodies of 
distinct specificities assemble identical VL domains with different VH domains. In 
contrast they found that rarely antibodies with different specificities have the same VH 
domain and very different VL. In the case of our anti PSCA mAbs we can suppose that 
the binding specificity and affinity of the antibodies is mainly due to the VH domain 
because it is the same in clone 1 and clone 2 and the two mAbs demonstrate comparable 
binding properties, whereas the different VL domains could be involved in a different 
role than the binding properties, like antibody stability. Since the two mAbs have no 
different binding properties clone 1 was selected for further characterization. 
The selected anti PSCA mAb was assessed by flow cytometry with different PSCA 
positive and negative cell lines. As SW780 is the only available cell line constitutively 
expressing PSCA with a variable expression depending on as yet unknown factors, PC-
3, LNCaP, HEK 293 and MDCK cell lines were stably transfected with hPSCA-
pcDNA3.1. The flow cytometric analysis confirmed the antibody clone 1 binding 
properties to the antigen and its specificity. To assess the possible use of our antibody 
for diagnostic/therapeutic purposes, the concentration of antibody necessary to saturate 
the 50% of antigenic sites was determined by flow cytometry. The binding curves 
obtained incubating cells with increasing concentrations of mAb were determined for 
two different cell lines: PC-3 hPSCA and LNCaP hPSCA.  The antibody reaches 
saturation of 50% of PSCA sites at the concentration of 16 nM and 23 nM respectively 
on PC-3 hPSCA and LNCaP hPSCA. To verify the reliability of the values obtained, the 
binding curve of anti Prostate Specific Membrane Antigen (PSMA) antibody was 
determined for LNCaP hPSCA cells which are able to express another tumor associated 
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antigen, namely PSMA. The anti PSMA mAb reaches saturation of 50 % of PSMA sites 
at the concentration of 8 nM. The values obtained for anti PSCA mAb are consistent 
with that obtained for the anti PSMA mAb and with the rage of 10-7-10-11 M for 
antibodies of biological interest. For this reason the anti PSCA mAb clone 1 was 
assessed for its diagnostic potential. First of all it has to be considered that the antigen 
PSCA has multiple N-glycosylation sites [Reiter et al.,1998], and that differences in the 
glycosylation pattern of antigens exist between healthy and malignant tissues [Pauli et 
al., 2003; Robbe-Messelot et al., 2008; Jankovic and Milutinovic, 2008] and could exist 
also between different patients. As our anti PSCA mAb was obtained by mice 
immunization with PSCA purified from bacteria, which is non glycosylated, the mAb 
was assessed by Western Blot with MDCK hPSCA cell lysate and subsequently with 
tumor tissue lysates from different patients to verify its ability to recognize the possible 
glycosylated isoforms of the antigen. MDCK cells were chosen because they are a well 
differentiated cell line with tight junctions that form polarized monolayers in culture 
closely reproducing the epithelial tissue organization in vivo. A Western Blot assay 
performed with this transfected cell line demonstrated that our mAb is able to recognize 
different isoforms of the PSCA. In fact in the total lysate are present many bands with a 
molecular weight between 25 kDa and 40 kDa. The PSCA pattern of glycosylation was 
verified by treating the total lysate with two endoglycosidases: Endoglycosidase H and 
N-Glycosidase F. The band at 40 kDa corresponds to the antigen bound to complex 
sugars, in fact it shifts to 15 kDa only after treatment with N-Glycosidase F which 
cleaves mannose rich, hybrid and complex glycans. The bands at 25-35 kDa correspond 
to the antigen bound to hybrid sugars, in fact they partially shift to 22 kDa after 
treatment with Endoglycosidase H, which cleaves only mannose rich glycans, and 
completely to 15 kDa after treatment with N-Glycosidase F. Because our antibody is 
able to recognize different PSCA isoforms it was assessed also in Western Blot with 
prostate and pancreatic tumor tissue lysates from patients. It is interesting to observe 
that also in this case our anti PSCA mAb is able to recognize the antigen, that the PSCA 
has a unique pattern of glycosylation in each tissue lysate and that the PSCA molecular 
weight is the same in the tumor tissue analyzed. The antigen could be supposed to be 
glycosylated because it has a molecular weight of about 28 kDa. In the literature there is 
no information available as to the molecular weight of PSCA expressed in tumor tissues 
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because the PSCA expression analysis was performed by immunohistochemistry (IHC) 
or by flow cytometry. In future experiments it could be interesting to investigate if there 
is a correlation between the tumor stage and the pattern of glycosylation of PSCA which 
could be involved in the PSCA function which at the present time is still unknown.  
The Western Blot assay performed with tumor tissue lysates showed also that our 
antibody can recognize the antigen in three out of three prostate neoplastic tissue lysates 
and in two out of three pancreatic neoplastic tissue lysates. These results are consistent 
with the evidence that in IHC 94% of prostate tumors [Gu et al., 2000] and 60% of 
pancreatic adenocarcinomas [Argani et al., 2001] are positive for PSCA expression. 
Moreover our antibody could recognize a linear and non glycosylated epitope because it 
binds to the denatured and both glycosylated and non glycosylated antigen as assessed 
by Western Blot. 
The diagnostic potential of the anti-PSCA antibody was assessed also by ELISA with 
cell fixed with 2% paraformaldehyde. Paraformaldehyde, used in IHC to fix tissues, 
could alter the antigen structure and prevent antibody binding to the antigen. This 
experiment demonstrated that the antibody can recognize the antigen also on fixed cells. 
All the binding properties examinated for our anti PSCA mAb clone 1 led us to consider 
it as a potential tool for diagnostic purposes. It will be important to assess the antibody 
performance also by the IHC technique. Moreover the antibody could be conjugated to 
fluorescent tracers or radionuclides and then be assessed for in vivo immuno-imaging 
approaches; this technique could improve the diagnosis of micrometastases. 
Preliminary studies were also performed to analyze the therapeutic potential of our anti 
PSCA mAb clone 1. Many antibodies are approved by FDA or are in clinical trials to 
evaluate their therapeutic use in cancer therapy. First of all the proliferation assay 
performed with PC-3 hPSCA cells demonstrated that the antibody alone is not able to 
induce cell death through a direct effect, but it can kill cells after linkage to the A chain 
of Ricin (RTA). It is interesting to observe that Gu et al., 2005 demonstrated that their 
anti PSCA mAb, 1G8, induces cell death in vitro through a direct, Fc-independent 
mechanism. Probably the difference in cell killing between the two anti PSCA 
antibodies, clone 1 and 1G8, could be due to the recognition of different epitopes. It is 
interesting to observe that the binding to different PSCA epitopes could induce or not 
cell apoptosis. 
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The anti PSCA-RTA immunotoxin obtained by chemical linkage of anti PSCA clone 1 
mAb to RTA was assessed on PC-3 hPSCA and PC-3 WT cell lines. A proliferation 
assay demonstrated that the chemical immunotoxin has a 100 fold higher cytotoxic 
activity in PC-3 hPSCA cells compared with the RTA toxin alone, that is the active 
enzymatic domain. Moreover the anti PSCA-RTA immunotoxin has a 100 fold lower 
toxicity on PC-3 WT cells than on PC-3 hPSCA cells and the same toxicity as RTA on 
PC-3 WT cells. These results demonstrate that the greater toxicity of the immunotoxin 
is due to the specific binding of anti PSCA mAb to the PSCA antigen. The anti PSCA 
clone 1 antibody could be considered as a good vehicle for the delivery of toxic 
molecules to tumor cells overexpressing the antigen PSCA. 
The monoclonal antibody described in this thesis is murine and because of this it cannot 
be administered to patients who could develop human–antimouse antibodies (HAMAs). 
Moreover the large size of the antibodies limits tumor penetration, and their long serum 
half-life is not suitable for applications such as radioimmunotherapy or imaging. To 
overcome these problems the recombinant DNA technology allows to generate 
fragments that retain the binding activity of the full-length molecule and that, thanks to 
their reduced size, demonstrate high tumor penetration, very rapid plasma clearance and 
lower immunogenicity. For this reason the variable heavy (VH) and light (VL) chain of 
our anti PSCA antibody were cloned to obtain the variable fragment scFv. 
The anti PSCA scFv was produced in a bacterial strain and then purified from the 
periplasmic fraction. The scFv binding properties were assessed by ELISA, using 
recombinant PSCA, by flow cytometry, using positive and negative cell lines, and by 
the SPR technology. The scFv demonstrated to be able to recognize the antigen PSCA 
with the same specificity but lower affinity than the parental whole mAb. This is 
consistent with the monovalent binding moiety of the scFv and the divalent binding 
moiety of the whole mAb; in fact the ability to bind to two antigen sites greatly 
increases the functional affinity [Holliger and Hudson, 2005]. The Biacore analysis 
moreover determined the kinetic parameters of scFv and Fab, derived from the whole 
mAb. The KD of scFv and Fab are 2.29 x 10-8 M and 1.41 x 10-8 M respectively. This 
means that the recombinant fragment scFv maintains the same binding properties as the 
parental Fab. It is interesting to observe that the scFv partially recovered its affinity 
when it was made artificially divalent by cross-linking scFv monomers via an antibody-
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mediated myc-tag interaction. This was possible because the scFv was cloned in an 
expression vector which appended a myc-tag to the C-terminus of the scFv. These data 
suggest that it could be possible to generate PSCA specific fragments with higher 
affinity by generating a divalent minibody or diabody. For the generation of antibody 
fragments for cancer therapy/diagnosis, it is important to consider another factor: “the 
binding site barrier effect”. Antibodies with high affinity bind tightly to their antigen 
upon the first encounter, that is, at the periphery of the tumor. So they do not penetrate 
deeper inside the tumor until all antigen molecules are saturated in the periphery. By 
contrast moderate binders are released from these first encountered antigens and 
penetrate deeper into the tumor, ultimately leading to uniform intratumoral distribution 
and higher tumor uptake. For this reason an scFv with low affinity could be better suited 
for tumor targeting. The recombinant DNA technology could be also exploited for the 
humanization and the engineering of the optimal affinity of the anti PSCA scFv 
characterized in this thesis. As regards the affinity optimization by protein engineeering 
techniques it would be important to balance the binding properties of the antibody 
leading to an efficient tumor targeting with the tumor retention effects that influence the 
diffusion of therapeutic molecules within the tumor.  
A fusion immunotoxin (scFv-PE40) was also created to obtain a more stable 
immunotoxin with reproducible chemical properties due to the obligatory 1:1 
antibody:toxin ratio. The immunotoxin was produced in a bacteria strain and it was 
accumulated in the inclusion bodies. Preliminary results obtained by flow cytometry 
with PSCA positive cell lines showed that the interaction of scFv with the PSCA is 
preserved after fusion to PE40. The efficacy of purified scFv-PE40 will be analysed in 
vitro using positive and negative cell lines. Moreover it will be important to study the 
efficacy of anti PSCA immunotoxins in MDCK cells, a polarized cell line which closely 
resemble epithelial tissue. Subsequently in vivo models will also be useful to study the 
in vivo effects of this new drug. 
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